Known human immunodeficiency virus (HIV) infection and/or active hepatitis B infection (defined as presence of Hep B DNA), active hepatitis C infection (defined as presence of Hep C RNA).
Patient has known active hepatitis B infection (defined as presence of hepatitis B surface antigen [HepB sAg] and/ or hepatitis B [Hep B] deoxyribonucleic acid [DNA]), active hepatitis C infection (defined as presence of Hep C RNA) and/or known human immunodeficiency virus (HIV); patients with HIV who have a normal CD4 count (>= 200) and an undetectable viral load are not excluded
Patients known to be HIV(+), Hep BsAg(+), or Hep C(+) are excluded as the effect of the agent on immune system has not been assessed
Patients with known active human immunodeficiency virus (HIV), hepatitis (hep) B, or hep C infection
Patients who have active, chronic, or on active treatment for Hep B or Hep C are excluded.
Patient has known active hepatitis B infection (defined as presence of hepatitis B [HepB] surface antigen [sAg] and/or Hep B deoxyribonucleic acid [DNA]), active hepatitis C infection (defined as presence of hepatitis C [Hep C] ribonucleic acid [RNA]) and/or known human immunodeficiency virus (HIV) carrier (HIV 1/2 antibodies)
Active hepatitis B infection (defined as presence of hepatitis [hep] B surface antigen [sAg] and/ or hep B deoxyribonucleic acid [DNA]), active hepatitis C infection (defined as presence of hep C ribonucleic acid [RNA]) and/or known human immunodeficiency virus (HIV) carrier
Known active hepatitis B infection (defined as presence of hepatitis B [HepB] surface antigen [sAg] and/or Hep B deoxyribonucleic acid [DNA]), known active hepatitis C infection (defined as presence of hepatitis C [Hep C] ribonucleic acid [RNA]) and/or known human immunodeficiency virus (HIV) carrier
Active infections including hepatitis B carrier status, hepatitis C virus (HCV) infection (patients must have a negative hepatitis [hep] B and hep C viral load at screening)
Patients with known active human immunodeficiency virus (HIV), hepatitis (Hep) B, or Hep C infection will be excluded; if not clinically indicated, the patients do not need to be tested
Has active hepatitis B or hepatitis C infection; patients with a history of hepatitis B/C infection who have received anti-viral therapy and are disease free (hepatitis [Hep] B - negative hepatitis B surface antigen [HBsAg] and HBV deoxyribonucleic acid [DNA]; Hep C – negative HCV ribonucleic acid [RNA]) may be considered for enrollment after discussion with principal investigator
Clinically significant infection, including known human immunodeficiency virus (HIV) or hepatitis C infection, or known hepatitis B (Hep B) surface antigen positivity; patients with Hep B core positivity can be enrolled if the Hep B polymerase chain reaction (PCR) is negative, and they are on antiviral suppression
Active hepatitis B (hepatitis [Hep] B core antibody positive and subsequent Hep B surface antigen positive or Hep B deoxyribonucleic acid [DNA] positive) or hepatitis C infection (Hep C antibody positive and subsequent detectable viral load)
Active infection including hepatitis B-carrier status, hepatitis C virus (HCV) infection (patients must have a negative hepatitis [Hep] B and Hep C viral load at screening)
Patient has known active hepatitis B infection (defined as presence of hepatitis B [HepB] surface antigen (sAg) and/ or Hep B deoxyribonucleic acid [DNA]), active hepatitis C infection (defined as presence of hepatitis C [Hep C] ribonucleic acid [RNA]) and/or known human immunodeficiency virus (HIV) carrier (HIV 1/2 antibodies)
Active hepatitis B infection (defined as presence of hepatitis B [Hep B] surface antigen [sAg] and/or Hep B deoxyribonucleic acid [DNA]), active hepatitis C infection (defined as presence of hepatitis C [Hep C] ribonucleic acid [RNA]) and/or known human immunodeficiency virus (HIV) carrier
Virus or active hepatitis B virus infection; patients who are hepatitis B core antibody (Hep B cAb) positive may be eligible as long as there is no evidence of active infection with negative hepatitis B (Hep B) by polymerase chain reaction (PCR); in this case, Hep B PCR must be monitored monthly
Known HIV, or active hep B or hep C infection (detected positive by PCR).
Serologic or clinical evidence of current active hepatitis B or C infection, defined as elevated levels of hepatitis (Hep) B antigen or Hep C antibody (unless active infection is ruled out by nucleic acid tests)
Positive screening tests for human immunodeficiency virus (HIV), hepatitis (Hep) B, Hep C, active tuberculosis or recent (< 2 week ago) clinically significant infection or evidence of active HIV, Hep B, or Hep C. (Note: If positive results are not indicative of true active or chronic infection, the patient can be treated.)
Positive screening tests for HIV, Hep B, and Hep C. If positive results are not indicative of true active or chronic infection, the patient can be treated.
Known hepatitis (hep) B or C, or known cirrhosis (screening for viral hepatitis is not required)
Positive screening tests for human immunodeficiency virus (HIV), hepatitis (Hep) B, and Hep C; if positive results are not indicative of true active or chronic infection, the patient can be treated
Known history of human immunodeficiency virus (HIV), hepatitis B, and/or hepatitis C (no additional laboratory tests for HIV, hepatitis [Hep] B, or Hep C are required for screening)
Patients must not have a known history of active hepatitis B infection (defined as presence of hepatitis B surface antigen [Hep B sAg] and/ or Hep B deoxyribonucleic acid [DNA]), active hepatitis C infection (defined as presence of hepatitis C [Hep C] ribonucleic acid [RNA]) and/or known human immunodeficiency virus (HIV) seropositive
CLINICAL/LABORATORY CRITERIA: Patients must not have a known history of active hepatitis B or C infection (defined as presence of hepatitis [Hep] B surface antigen [sAg] and/or Hep B deoxyribonucleic acid [DNA] and/or Hep C ribonucleic acid [RNA]); patients must not have a known history of human immunodeficiency virus (HIV) seropositivity
Subject has active hepatitis B or C. Subject with hepatitis in medical history may be eligible if infection considered cleared, ie core Ab+, surface Ab+, surface Ag- for hep B and Ab+/DNA- for hep C.
History of active or chronic hepatitis (e.g. Hep B or C)
No positive Hep C serology or active Hep B infection
Positive screening tests for human immunodeficiency virus (HIV), hepatitis B virus (Hep B), and hepatitis C virus (Hep C). If positive results are not indicative of true active or chronic infection, the patient can be treated.
Positive screening tests for human immunodeficiency virus (HIV), hepatitis B (hep B), and hepatitis C (hep C) (referencing blood draw at leukapheresis screening); if positive results are not indicative of true active or chronic infection, the patient can be treated
Hep B and Hep C
known diagnosis of human immunodeficiency virus or chronic active Hep B or C.
Active, life threatening or clinically significant uncontrolled systemic infection, known human immunodeficiency virus (HIV)-related illness, hepatitis B (Hep B) or hepatitis C (Hep C) infection
Positive serological test for HIV, Hep B or Hep C or history of HIV infection, Hepatitis B or Hepatitis C (women with cured HCV will be allowed; subject must have had an serologic test performed within 12 months of informed consent);
Current or chronic hepatitis B or C infection, or known seropositivity for human immunodeficiency virus (HIV); Note: patients with previous history of hepatitis B (who have cleared the infection and have natural immunity, i.e. hepatitis [Hep] B core antibody positive cases) are excluded if prophylaxis against Hep B reactivation with antiviral agents (such as entecavir) is recommended, after consultation with gastroenterologist/hepatologist or infectious disease team
active (acute or chronic) or uncontrolled severe infection, liver disease such as cirrhosis, decompensated liver disease (except for Hep B and Hep C positive patients)
Patients with known human immunodeficiency virus (HIV) or hepatitis B or C are excluded
Participant is known to be positive for Human Immunodeficiency Virus (HIV), Hepatitis B, or Hepatitis C
Prior or current history of hepatitis B, hepatitis C or human immunodeficiency virus
12. Known to be human immunodeficiency virus (HIV) positive, hepatitis B, or hepatitis C positive;
Has a known history of or screens positive for Human Immunodeficiency Virus (HIV), active chronic or acute Hepatitis B or Hepatitis C.
Known positive for human immunodeficiency virus (HIV) or infectious hepatitis, type A, B or C or active hepatitis
Positive for human immunodeficiency virus (HIV) or hepatitis B or C
Human immunodeficiency virus (HIV), hepatitis B or C, or severe/uncontrolled infections or concurrent illness, unrelated to the tumor, requiring active therapy
Prior or current history of hepatitis B, hepatitis C or human immunodeficiency virus
History of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
Known chronic infections with human immunodeficiency virus (HIV), hepatitis B or C; participants with a history of resolved hepatitis A may be included in the trial
No known hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) seropositivity; testing is not required in absence of clinical suspicion
Known positive status for human immunodeficiency virus (HIV) and/or active hepatitis B or C.
Positive test for human immunodeficiency virus and/or active hepatitis B or hepatitis C or tuberculosis
History of human immunodeficiency virus (HIV), interstitial lung disease, active Hepatitis B or Hepatitis C, or ?Grade 3 immune-related AE with prior immunotherapy
Known immunodeficiency or known to have evidence of acute or chronic or human immunodeficiency virus (HIV), Hepatitis B, or Hepatitis C or other uncontrolled inter-current illnesses.
Known to be serologically positive for hepatitis B, hepatitis C or human immunodeficiency virus (HIV)
Participants with known history of human immunodeficiency virus (HIV) or active Hepatitis B or C virus
The patient has known positive status for human immunodeficiency virus active or chronic Hepatitis B or Hepatitis C.
Positive for human immunodeficiency virus (HIV) or hepatitis B or C
Active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive; hepatitis and HIV testing are not required prior to the start of treatment
Known hepatitis B, hepatitis C, or human immunodeficiency virus (HIV)
Known immunodeficiency, human immunodeficiency virus (HIV) positivity, hepatitis B, or hepatitis C
Positive serology for human immunodeficiency virus (HIV), hepatitis B or hepatitis C
Human immunodeficiency virus (HIV) positive; active hepatitis B or C;
Negative antiviral serology for human immunodeficiency virus (HIV), hepatitis B, and hepatitis C.
Patients with known positivity for human immunodeficiency virus (HIV) or hepatitis C; baseline testing for HIV and hepatitis C is not required
Patients with known positivity for human immunodeficiency virus (HIV), or hepatitis C; baseline testing for HIV and hepatitis C is not required
History of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
Known to be positive for human immunodeficiency virus (HIV) or infectious hepatitis (type B or C)
Subjects with known human immunodeficiency virus (HIV), acute chronic hepatitis B virus surface antigen (HBsAg) or hepatitis C virus. (HIV-positive subjects are ineligible because of the potential for pharmacokinetic interactions of antiviral therapy with IACS-010759.)
Is human immunodeficiency virus (HIV) positive or has evidence of active hepatitis C virus or active hepatitis B virus; if initial test shows a positive result, no further testing will be done
Known positive test for human immunodeficiency virus (HIV), acquired immunodeficiency syndrome (AIDS), hepatitis A, hepatitis B, hepatitis C, or cytomegalovirus (CMV)
Known history of human immunodeficiency virus (HIV) positivity or active hepatitis C or B - chronic asymptomatic viral hepatitis is allowed
Human immunodeficiency virus (HIV), active hepatitis B or C
Acute hepatitis or known human immunodeficiency virus (HIV)
Human immunodeficiency virus (HIV) positive; active hepatitis B or C
Negative human immunodeficiency virus (HIV), hepatitis B and C, and tuberculosis (TB) test
Human immunodeficiency virus (HIV), hepatitis B or C documented infections
Known human immunodeficiency virus (HIV) or active hepatitis A, B, or C
Active hepatitis B, active hepatitis C, or positive for human immunodeficiency virus (HIV)
Patients with known chronic human immunodeficiency virus (HIV), hepatitis B or hepatitis C infections should be excluded
Human immunodeficiency virus (HIV) positive; active hepatitis B or C
Patients with known positivity for human immunodeficiency virus (HIV) or hepatitis C; baseline testing for HIV and hepatitis C is not required
Known prior or current history of human immunodeficiency virus (HIV) and/or hepatitis B/C
Serious infections including a history of active hepatitis B, hepatitis C or human immunodeficiency virus (HIV)
Subjects who active hepatitis B or C, or human immunodeficiency virus (HIV)
Known history of active tuberculosis (TB), human immunodeficiency virus (HIV) 1/2, hepatitis B or hepatitis C
Known history of human immunodeficiency virus (HIV) or active hepatitis C
Patients with known positivity for human immunodeficiency virus (HIV) or hepatitis C; baseline testing for HIV and hepatitis C is not required
Known positive serology for human immunodeficiency virus (HIV), active hepatitis B, and/or active hepatitis C infection
Known human immunodeficiency virus (HIV)-positive and on highly active antiretroviral therapy (HAART), and/or hepatitis B or C on treatment
Known positive serology for human immunodeficiency virus (HIV), active hepatitis B, and/or active hepatitis C infection
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies), active hepatitis B or hepatitis C
Known positive serology for human immunodeficiency virus (HIV), active hepatitis B, and/or active hepatitis C infection (note: if not suspected, testing is not required at baseline)
Known history of human immunodeficiency virus (HIV), hepatitis B or C
Patients with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
Human immunodeficiency virus (HIV) positive; active hepatitis B or C
Known positive status for human immunodeficiency virus (HIV) and/or active hepatitis B or C.
Known human immunodeficiency virus (HIV) or hepatitis C
An existing diagnosis of human immunodeficiency virus (HIV), hepatitis B, hepatitis C, or any current laboratory findings or clinical signs and symptoms that suggest these conditions
Known active human immunodeficiency virus (HIV), hepatitis B, or hepatitis C that has not been documented to be cured
Positive for human immunodeficiency virus (HIV), Hepatitis B, or Hepatitis C
Known positive serology for human immunodeficiency virus (HIV), active hepatitis B, and/or active hepatitis C infection
Human immunodeficiency virus (HIV) positive; active hepatitis B or C
Patients with known positivity for human immunodeficiency virus (HIV) or hepatitis C; baseline testing for HIV and hepatitis C is not required
Known positive serology for human immunodeficiency virus (HIV), active hepatitis B, and/or active hepatitis C infection
Human immunodeficiency virus (HIV), hepatitis B, hepatitis C
Patients known to be human immunodeficiency virus (HIV)-positive or have active hepatitis B or C
Known positive for human immunodeficiency virus (HIV) or with known active infectious hepatitis, type A, B or C
Known to be positive for human immunodeficiency virus (HIV) or infectious hepatitis (type B or C)
Positive test for hepatitis B hepatitis C, and / or human immunodeficiency virus (HIV) during screening, or within 3 months prior to first dose of study treatment
Known positive virology/serology for human immunodeficiency virus (HIV)-1, HIV-2, hepatitis B (surface antigen), or hepatitis C.
Patients with known human immunodeficiency virus, active hepatitis B or active hepatitis C
Subject is positive for human immunodeficiency virus (HIV-1) chronic or active hepatitis B, or active hepatitis A or C
Known positive serology for human immunodeficiency virus (HIV), active hepatitis B, and/or active hepatitis C infection
Negative screening test results for hepatitis B, hepatitis C, and human immunodeficiency virus
Patients known positive for human immunodeficiency virus (HIV), or infectious hepatitis type B or C
Known history of human immunodeficiency virus (HIV) or hepatitis C (baseline testing is not required)
Known chronic infections with human immunodeficiency virus (HIV), hepatitis B or C
Subjects with known seropositivity to human immunodeficiency virus (HIV), positive\n             for Hepatitis B, positive for Hepatitis C (antigen positive), or known hepatic\n             cirrhosis
Patients with chronic human immunodeficiency virus (HIV), hepatitis B or hepatitis C infections should be excluded
Subjects with known history of cirrhosis, human immunodeficiency virus (HIV), hepatitis B or C
Patients with chronic human immunodeficiency virus (HIV), hepatitis B or hepatitis C infections should be excluded
Known human immunodeficiency virus (HIV), hepatitis B or C-positive patients (active, previously treated or both)
Patients with human immunodeficiency virus (HIV) disease or active viral hepatitis
Known history of Human Immunodeficiency Virus (HIV), Hepatitis B or C
Human immunodeficiency virus (HIV) or hepatitis B or C
Known human immunodeficiency virus (HIV), or Hepatitis B or C.
Is positive for human immunodeficiency virus (HIV), chronic or active hepatitis B or active hepatitis A or C
The patient has known positive status for human immunodeficiency virus (HIV) active or chronic Hepatitis B or Hepatitis C.
Subjects is positive for human immunodeficiency virus (HIV); chronic or active hepatitis B or active hepatitis A, or C
Positive for human immunodeficiency virus (HIV), Hepatitis B or C
Is positive for human immunodeficiency virus (HIV), chronic or active hepatitis B or active hepatitis A or C
Known active or chronic hepatitis B or C or human immunodeficiency virus (HIV)
Patients with human immunodeficiency virus (HIV), chronic hepatitis B, or chronic hepatitis C (known from the existing medical record)
Positive human immunodeficiency virus (HIV) or hepatitis B or C
Known human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
Human immunodeficiency virus (HIV), active hepatitis B or C, or tuberculosis
Known positive for human immunodeficiency virus (HIV) or infectious hepatitis, type A, B or C
Subjects with positive human immunodeficiency virus (HIV) or hepatitis C at baseline by self-report
Known positive serology for human immunodeficiency virus (HIV), active hepatitis B, and/or active hepatitis C infection
Patients with known history of human immunodeficiency virus (HIV) or hepatitis B
Known history of human immunodeficiency virus (HIV), hepatitis B or hepatitis C
Subjects with positive human immunodeficiency virus (HIV) or hepatitis C at baseline by self report
Known history or active human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
Patients with fever or any active systemic infections, including known human immunodeficiency virus (HIV), hepatitis B or C
Known positive for human immunodeficiency virus (HIV) or hepatitis B or C per institutional standard of care
Known human immunodeficiency virus (HIV), or active hepatitis B or hepatitis C
Known history of human immunodeficiency virus (HIV), hepatitis B or hepatitis C
Known positive status for human immunodeficiency virus or active or chronic Hepatitis B or Hepatitis C.
Hepatitis B or C or human immunodeficiency virus (HIV)
Known history of human immunodeficiency virus (HIV) and/or active Hepatitis B or C infections
Known positive for human immunodeficiency virus (HIV), chronic or active hepatitis B or C
Known diagnosis of human immunodeficiency virus (HIV) or hepatitis C (testing is not mandatory)
Human immunodeficiency virus (HIV)-positive patients or with history of hepatitis or with current chronic or active hepatitis; a past history of hepatitis A is allowed
Known to be human immunodeficiency virus (HIV) positive or has untreated, active hepatitis B.
Has a known history of Human Immunodeficiency Virus (HIV) or Hepatitis C (baseline testing is not required).
Known history of human immunodeficiency virus (HIV), active Hepatitis B or C
Known history of Human Immunodeficiency Virus (HIV), Hepatitis B or Hepatitis C
Positive test for human immunodeficiency virus (HIV) and/or active hepatitis B or hepatitis C or tuberculosis
Known positive serology for human immunodeficiency virus (HIV), active hepatitis B, and/or active hepatitis C infection
Participant is known to be seropositive for human immunodeficiency virus (HIV), known to have hepatitis B surface antigen positivity, or history of to have a history of hepatitis C
Patients must be test negative for human immunodeficiency virus (HIV), hepatitis B and C
Subject is human immunodeficiency virus (HIV) positive or has chronic hepatitis B or hepatitis C virus requiring treatment
Known diagnosis of human immunodeficiency virus, hepatitis B, or hepatitis C.
Human immunodeficiency virus (HIV), hepatitis B or C, or severe/uncontrolled infections or intercurrent illness, unrelated to the tumor, requiring active therapy
Known human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
Positive test for human immunodeficiency virus (HIV) and/or active hepatitis B or hepatitis C or tuberculosis
Patients with known positivity for human immunodeficiency virus (HIV), or hepatitis C; baseline testing for HIV and hepatitis C is not required
Patients with known human immunodeficiency virus (HIV), hepatitis B or hepatitis C (active or carriers)
Hepatitis B or C or known human immunodeficiency virus (HIV) positive
Subjects with known diagnosis of human immunodeficiency virus (HIV) or chronic active Hepatitis B or C; viral testing is not required; subjects with a history of Hepatitis B and/or C are allowed on trial if the virus is undetected at the time of enrollment
Patients known to be human immunodeficiency virus (HIV) or hepatitis B and/or C positive are not eligible for participation; NOTE: HIV and hepatitis testing is not required for study participation
Known positive serology for the human immunodeficiency virus (HIV), active hepatitis B and/or active hepatitis C.
Known positive for human immunodeficiency virus (HIV) or infectious hepatitis, type A, B or C
Active human immunodeficiency virus (HIV), hepatitis B and hepatitis C
Negative serology tests for human immunodeficiency virus (HIV) Ab/Ag Combo, and for active hepatitis B or hepatitis C, within 14 days of first peripheral blood collection for sipuleucel-T
Known history of human immunodeficiency virus (HIV), hepatitis B and hepatitis C (testing is not necessary if patient does not have history of these diseases, and no risk factors for acquisition of these viruses)
Known positive for human immunodeficiency virus (HIV) or infectious hepatitis, type B or C
Active hepatitis C or positive tests for human immunodeficiency virus (HIV)
Patients who are known to be human immunodeficiency virus (HIV), hepatitis B, or hepatitis C positive
Known positivity for human immunodeficiency virus (HIV) or hepatitis C with uncontrolled disease; baseline testing for HIV and hepatitis C is not required
Patient is known to be positive for human immunodeficiency virus (HIV) or infectious hepatitis, type A, B, or C
Negative virology/serology for human immunodeficiency virus (HIV)-1, HIV-2, hepatitis B (surface antigen), and hepatitis C
Positive for HIV (Human Immunodeficiency Virus) or with active hepatitis B and/or C
Subjects known to be infected with human immunodeficiency virus (HIV), hepatitis B or hepatitis C.
Is positive for Human Immunodeficiency Virus (HIV) and/or Hepatitis B or C
Documented negative serologic testing for human immunodeficiency virus (HIV), hepatitis B (unless serologically positive due to prior vaccination), and hepatitis C within the year prior to enrollment (note: for guidance in defining active infection for hepatitis B, please refer to the WHO guidelines)
Known human immunodeficiency virus (HIV) and/or active Hepatitis B or C infections
Known positive serology for human immunodeficiency virus (HIV), active hepatitis B, and/or active hepatitis C infection
Known clinically significant infections, including human immunodeficiency virus (HIV) and active hepatitis B or C
Patients with known human immunodeficiency virus (HIV) or Hepatitis B or C (active, previously treated or both)
positive serology for human immunodeficiency virus (HIV), hepatitis B or hepatitis C or have HIV-AIDS, or active hepatitis B or C.
Patients with known human immunodeficiency virus (HIV), or known active hepatitis B or C infections
Patients with known human immunodeficiency virus (HIV) or hepatitis B or C
Positive for human immunodeficiency virus (HIV) or hepatitis B or C
Known positive for human immunodeficiency virus (HIV), chronic or active hepatitis B or active hepatitis A or C
Patients with known positivity for human immunodeficiency virus (HIV) or hepatitis C; baseline testing for HIV and hepatitis C is not required
Clinically significant infections including human immunodeficiency virus (HIV), syphilis, and active hepatitis B or C
Known to be infected with human immunodeficiency virus (HIV), hepatitis B or hepatitis C viruses
Patients with known positivity for human immunodeficiency virus (HIV) or hepatitis C; baseline testing for HIV and hepatitis C is not required.
Patients with known active hepatitis B, C or human immunodeficiency virus (HIV) infections on initial assessment
Known or tests positive for human immunodeficiency virus, hepatitis B, or hepatitis C
Known positive for human immunodeficiency virus (HIV) or infectious hepatitis, type A, B or C
Known positive serology for the human immunodeficiency virus (HIV), active hepatitis B and/or hepatitis C.
Known positive serology for human immunodeficiency virus (HIV), active hepatitis B, and/or active hepatitis C infection
Subjects who are known to have a history of or active human immunodeficiency virus (HIV) or active hepatitis B and/or C
Known positive serology for the human immunodeficiency virus (HIV), active hepatitis B and/or hepatitis C.
Known to be positive for human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
Patients with known human immunodeficiency virus (HIV), hepatitis B or C (however, if patients have previously been treated for hepatitis B or C and have undetectable viral loads, they can be considered eligible for trial)
Known diagnosis of human immunodeficiency virus (HIV), Hepatitis B or C (testing is not mandatory for study entry)
Patients with chronic human immunodeficiency virus (HIV), hepatitis B or hepatitis C infections should be excluded because of potential effects on immune function and/ or possible drug interactions
Patients with chronic human immunodeficiency virus (HIV), hepatitis B or hepatitis C infections are excluded
Known positive test for human immunodeficiency virus (HIV), hepatitis C, or hepatitis B surface antigen.
Patients with known positivity for human immunodeficiency virus (HIV) or hepatitis C; baseline testing for HIV and hepatitis C is not required
Known positive serology for the human immunodeficiency virus (HIV), active hepatitis C, and/or active hepatitis B.
The patient has known positive status for human immunodeficiency virus (HIV), active or chronic Hepatitis B or Hepatitis C.
Patients with known positivity for human immunodeficiency virus (HIV) or hepatitis B or C; baseline testing for HIV and hepatitis C is not required
Known positive status for human immunodeficiency virus (HIV) and/or active hepatitis B or C
Known human immunodeficiency virus (HIV), hepatitis B virus, or hepatitis C virus positive status
Patients with known positivity for human immunodeficiency virus (HIV) or hepatitis C; baseline testing for HIV and hepatitis C is not required; this is due to the unknown effects of AMG102
Patients known to be positive for human immunodeficiency virus (HIV) or infectious hepatitis, type B or C requiring active therapy (hepatitis B seropositivity due to hepatitis [Hep] B virus vaccine is not an exclusion); patients on combination antiviral therapy are ineligible; appropriate studies will be undertaken in this patient population
Human immunodeficiency virus (HIV) positive; active hepatitis B or C
Positive history of human immunodeficiency virus (HIV), active hepatitis B or active hepatitis C or severe/uncontrolled intercurrent illness or infection
Known hepatitis B, hepatitis C, or human immunodeficiency virus (HIV)
Known (historical) positive human immunodeficiency virus (HIV) serology, active hepatitis B, or active hepatitis C infection
Known positive serology for HIV (human immunodeficiency virus), active hepatitis B, and/or active hepatitis C infection
Known history of hepatitis B, C or human immunodeficiency virus (HIV)
Patients must not have known history of hepatitis B, hepatitis C, human immunodeficiency virus (HIV); the use of physiologic doses of corticosteroids may be approved after consultation with the study chair
Patients with a known history of human immunodeficiency virus (HIV), hepatitis B, and/or hepatitis C (testing not required as part of screening)
History of human immunodeficiency virus (HIV), hepatitis B, and/or hepatitis C
Known chronic active hepatitis B or hepatitis C; human immunodeficiency virus (HIV)-positive patients receiving or are candidates for antiretroviral therapy are also excluded
No known history of human immunodeficiency virus (HIV) or active hepatitis B or C
Patients with a diagnosis of hepatitis or human immunodeficiency virus (HIV)
Patients with known active hepatitis B, hepatitis C, or seropositive human immunodeficiency virus (HIV); testing is not required in the absence of clinical suspicion
History of human immunodeficiency virus (HIV) or active hepatitis C
Known serious infections, including a history of active hepatitis B, hepatitis C, or human immunodeficiency virus (HIV); screening for these infections is not required for study enrollment
Positive for human immunodeficiency virus (HIV) or active infections for hepatitis B, and/or hepatitis C, based on medical history
Subjects with positive human immunodeficiency virus (HIV) or hepatitis C at baseline
Known to be infected with human immunodeficiency virus (HIV), hepatitis B or hepatitis C viruses
Subject is positive for human immunodeficiency virus (HIV-1), chronic or active hepatitis B, or active hepatitis A or C
Human immunodeficiency virus (HIV) positive or active hepatitis
Documented negative serologic testing for human immunodeficiency virus (HIV), hepatitis B (unless serologically positive due to prior vaccination), and hepatitis C =< 1 year prior to registration
Subjects must not have a history of human immunodeficiency virus, hepatitis B, or hepatitis C, except for the following:
Is known to be human immunodeficiency virus (HIV) positive and/or known to have active chronic or acute Hepatitis B or Hepatitis C
Known history of human immunodeficiency virus (HIV), or active Hepatitis B or C.
Seropositivity for the human immunodeficiency virus
Hepatitis B or C infection, or known seropositivity for human immunodeficiency virus (HIV)
Known human immunodeficiency virus (HIV) seropositivity
Seropositivity for HIV.
A known history of human immunodeficiency virus (HIV) seropositivity
Known human immunodeficiency virus (HIV) seropositivity or active hepatitis B or C viral infection
Known or suspected human immunodeficiency (HIV) infection, known HIV seropositivity
A known history of HIV seropositivity or known immunodeficiency
Known HIV seropositivity
Known seropositivity for human immunodeficiency virus
Have a known history of HIV seropositivity
Seropositivity for HTLV-1.
Known hepatitis B or C infection, or known seropositivity for human immunodeficiency virus (HIV)
Human Immunodeficiency Virus (HIV) seropositivity
Human immunodeficiency virus (HIV) seropositivity.
Known Human Immunodeficiency Virus seropositivity
Known seropositivity for or active infection by human immunodeficiency virus (HIV).
Seropositivity for human immunodeficiency virus (HIV)
Known history of human immunodeficiency virus (HIV) seropositivity (HIV testing is not mandatory)
Human immunodeficiency virus (HIV) seropositivity, or active hepatitis B or C infection based on testing performed within 4 weeks of enrollment.
A known history of human immunodeficiency virus (HIV) seropositivity or known immunodeficiency; HIV testing will not be required as part of this trial, unless HIV is clinically suspected
Patients with known human immunodeficiency virus seropositivity will be excluded
Human immunodeficiency virus (HIV) seropositivity
Current or chronic hepatitis B or C infection, or known seropositivity for human immunodeficiency virus (HIV)
Seropositivity for the human immunodeficiency virus (HIV)
Known human immunodeficiency virus (HIV) seropositivity\r\n* Note: HIV testing is not required
Patients who are known to have HIV infection/seropositivity.
Known history of human immunodeficiency virus (HIV) seropositivity
Known human immunodeficiency virus (HIV) seropositivity\r\n* Note: HIV testing is not required
Known history of human immunodeficiency virus (HIV) seropositivity
Current or chronic hepatitis B or C infection, or known seropositivity for human immunodeficiency virus (HIV)
Current or chronic hepatitis B or C infection, or known seropositivity for human immunodeficiency virus (HIV)
Patients with known human immunodeficiency virus seropositivity will be excluded
Known history of human immunodeficiency virus (HIV) seropositivity
Active hepatitis B or C infection, or known seropositivity for human immunodeficiency virus (HIV)
Human immunodeficiency virus (HIV) seropositivity
Known history of human immunodeficiency virus (HIV) seropositivity
COHORTS 1 AND 2: HEALTHY VOLUNTEERS: Subjects with a primary or acquired immunodeficiency, including human immunodeficiency virus (HIV) seropositivity
EBV seropositivity
Known human immunodeficiency virus (HIV) seropositivity
Known human immunodeficiency virus seropositivity.
Known human immunodeficiency virus (HIV) seropositivity
A known history of human immunodeficiency virus (HIV) seropositivity
A known history of human immunodeficiency virus (HIV) seropositivity
Known human immunodeficiency virus (HIV) seropositivity
A known history of human immunodeficiency virus (HIV) seropositivity
Known human immunodeficiency virus (HIV) seropositivity
Known seropositivity for or active infection by human immunodeficiency virus (HIV)
Patients must not have a known history of human immunodeficiency virus (HIV) seropositivity
Patients must not have known human immunodeficiency virus (HIV)-1 seropositivity
Human immunodeficiency virus (HIV) seropositivity
Unrelated Donor: HIV seropositivity
known seropositivity for or history of active viral infection with human immunodeficiency virus (HIV)
Human immunodeficiency virus (HIV) seropositivity
Subject who has known seropositivity for or active infection for human immunodeficiency virus (HIV) or hepatitis C virus (HCV).
Known history of human immunodeficiency virus (HIV) seropositivity (HIV testing is not mandatory)
Known history of human immunodeficiency virus (HIV) or hepatitis B or C seropositivity
Known human immunodeficiency virus seropositivity.
Known human immunodeficiency virus (HIV) seropositivity
HIV seropositivity
Patients who have a known history of human immunodeficiency virus (HIV) seropositivity
Current or chronic hepatitis B or C infection, or known seropositivity for human immunodeficiency virus (HIV)
Human immunodeficiency virus (HIV) seropositivity
Patients must not have a known history of human immunodeficiency virus (HIV) seropositivity
Known history of human immunodeficiency virus (HIV) seropositivity
Known human immunodeficiency virus seropositivity
Known human immunodeficiency virus (HIV) seropositivity
Known or suspected human immunodeficiency virus (HIV) infection, known HIV seropositivity
Human immunodeficiency virus (HIV) seropositivity
A known history of human immunodeficiency virus (HIV) seropositivity as everolimus has immunosuppressant properties
Patients with a known history of human immunodeficiency virus (HIV) seropositivity
DONOR: HIV seropositivity
Patients with known human immunodeficiency virus (HIV) seropositivity
A known history of human immunodeficiency virus (HIV) seropositivity
History of seropositivity for human immunodeficiency virus (HIV)
DONOR: Human immunodeficiency virus (HIV) seropositivity
Human immunodeficiency virus (HIV) seropositivity
DONOR: HIV seropositivity
HIV or HTLV I/II seropositivity
Known human immunodeficiency virus (HIV) seropositivity
Patients with known human immunodeficiency virus seropositivity will be excluded
Known history of human immunodeficiency virus (HIV) seropositivity
Known human immunodeficiency virus seropositivity.
A known human immunodeficiency virus (HIV) seropositivity
A known history of human immunodeficiency virus (HIV) seropositivity
A known history of human immunodeficiency virus (HIV) seropositivity
Known seropositivity for human immunodeficiency virus (HIV)
Known history of human immunodeficiency virus (HIV) seropositivity
Known history of human immunodeficiency virus (HIV) seropositivity
Known history of HIV seropositivity;
Known active human immunodeficiency virus (HIV) infection or HIV seropositivity
No history of the following:\r\n* Active known or suspected autoimmune disease\r\n* Patients with human immunodeficiency virus (HIV) are eligible if the lymphocytes > 350 cluster of differentiation (CD)4+ cells and no detectable viral load\r\n* Symptomatic, untreated, or uncontrolled brain metastases present\r\n* Active autoimmune colitis \r\n* Autoimmune panhypopituitarism \r\n* Autoimmune adrenal insufficiency \r\n* Known active hepatitis B or C\r\n** Hepatitis B can be defined as:\r\n*** Hepatitis B surface antigen (HBsAg) > 6 months\r\n*** Serum hepatitis B virus (HBV) deoxyribonucleic acid (DNA) 20,000 IU/ml (105 copies/ml), lower values 2,000-20,000 IU/ml (104-105 copies/ml) are often seen in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B\r\n*** Persistent or intermittent elevation in alanine aminotransferase (ALT)/alanine aminotransferase (AST) levels\r\n*** Liver biopsy showing chronic hepatitis with moderate or severe necroinflammation\r\n** Hepatitis C can be defined as:\r\n*** Hepatitis C antibody (Ab) positive\r\n*** Presence of hepatitis C virus (HCV) ribonucleic acid (RNA)\r\n* Known active pulmonary disease with hypoxia defined as:\r\n** Oxygen saturation < 85% on room air or\r\n** Oxygen saturation < 88% despite supplemental oxygen
No known active hepatitis B or C\r\n* Active hepatitis B can be defined as: \r\n** Hepatitis B virus surface antigen (HBsAg) detectable for > 6 months;\r\n** Serum hepatitis B virus (HBV) DNA 20,000 IU/ml (105 copies/ml); lower values 2,000-20,000 IU/ml (104-105 copies/ml) are often seen in hepatitis B virus e antigen (HBeAg)-negative chronic hepatitis B\r\n** Persistent or intermittent elevation in ALT/AST levels \r\n** Liver biopsy showing chronic hepatitis with moderate or severe necroinflammation\r\n* Active hepatitis C can be defined as: \r\n** Hepatitis C antibody (AB) positive AND \r\n** Presence of hepatitis C virus (HCV) RNA
No history of the following:\r\n* Child Pugh class B or C liver disease\r\n* “Chronic active” hepatitis defined as: \r\n** Hepatitis B surface antigen (HBsAg) > 6 months\r\n** Serum hepatitis B virus (HBV) deoxyribonucleic acid (DNA) 20,000 IU/ml (105 copies/ml), lower values 2,000-20,000 IU/ml (104-105 copies/ml) are often seen in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B\r\n** Persistent or intermittent elevation in alanine aminotransferase (ALT)/aspartate aminotransferase (AST) levels\r\n** Liver biopsy showing chronic hepatitis with moderate or severe necroin?ammation
Active hepatitis B, either active carrier (hepatitis B surface antigen positive [HBsAg +]) or viremic (hepatitis B virus [HBV] deoxyribonucleic acid [DNA] >= 10,000 copies/mL, or >= 2,000 IU/mL)
Active hepatitis B, either active carrier (hepatitis B surface antigen [HBsAg] +) or viremic (hepatitis B virus [HBV] deoxyribonucleic acid [DNA] >= 10,000 copies/mL, or >= 2,000 IU/mL)
Active hepatitis B, either active carrier (hepatitis B surface antigen positive [HBsAg +]) or viremic (hepatitis B virus [HBV] deoxyribonucleic acid [DNA] >=10,000 copies/mL, or >= 2,000 IU/mL)
Active hepatitis B, either active carrier (hepatitis B surface antigen positive [HBsAg +]) or viremic (hepatitis B virus [HBV] deoxyribonucleic acid [DNA] >= 10,000 copies/mL, or >= 2,000 IU/mL)
Active hepatitis B, either active carrier (hepatitis B virus surface antigen [HBsAg] +) or viremic (hepatitis B virus [HBV] deoxyribonucleic acid [DNA] >= 10,000 copies/mL, or >= 2,000 IU/mL)
Patients with active hepatitis B, either active carrier (hepatitis B surface antigen [HBsAg] +) or viremic (hepatitis b virus [HBV] deoxyribonucleic acid [DNA] >= 10,000 copies/mL, or >= 2,000 IU/mL)
Active hepatitis B, either active carrier (hepatitis B surface antigen [HBsAg] +) or viremic (hepatitis B virus [HBV] deoxyribonucleic acid [DNA] >= 10,000 copies/mL, or >= 2,000 IU/mL)
Active hepatitis B, either active carrier (hepatitis B surface antigen [HBsAg] +) or viremic (hepatitis B virus [HBV] deoxyribonucleic acid [DNA] >/= 10,000 copies/mL, or >= 2,000 IU/mL).
Patients with active hepatitis B, either active carrier (hepatitis B virus surface antigen [HBsAg] +) or viremic (hepatitis B virus [HBV] deoxyribonucleic acid [DNA] >= 10,000 copies/mL, or >= 2,000 IU/mL)
Hepatitis B virus deoxyribonucleic acid (DNA) levels >2,000 international units/mL.
No history of the following: \r\n* Active known or suspected autoimmune disease\r\n* Human immunodeficiency virus (HIV) with CD4+ count < 300 or detectable viral load; patients with HIV, undetectable viral load, and CD4+ count >= 300 are eligible\r\n* Known active hepatitis B or C\r\n** Hepatitis B can be defined as: \r\n*** Hepatitis B virus surface antigen (HBsAg) > 6 months\r\n*** Serum hepatitis B virus (HBV) deoxyribonucleic acid (DNA) 20,000 IU/ml (105 copies/ml), lower values 2,000-20,000 IU/ml (104-105 copies/ml) are often seen in hepatitis B virus e antigen (HBeAg)-negative chronic hepatitis B\r\n*** Persistent or intermittent elevation in alanine aminotransferase (ALT)/aspartate aminotransferase (AST) levels\r\n*** Liver biopsy showing chronic hepatitis with moderate or severe necroin?ammation\r\n** Hepatitis C can be defined as:\r\n*** Hepatitis C antibody (AB) positive\r\n*** Presence of hepatitis C virus (HCV) RNA\r\n* Known active pulmonary disease with hypoxia defined as oxygen saturation < 85% on room air
Active hepatitis B, either active carrier (hepatitis B surface antigen [HBsAg] +) or viremic (hepatitis B virus [HBV] DNA >= 10,000 copies/mL, or >= 2,000 IU/mL)
Active symptomatic fungal, bacterial and/or viral infection including active HIV or viral (A, B or C) hepatitis.
Active and clinically significant bacterial, fungal or viral infection including hepatitis B (HBV), hepatitis C (HCV), known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness; baseline viral assessment is not required in patients with no known infection
Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy. Known infection with human immunodeficiency virus, or an active infection with hepatitis B or hepatitis C.
Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy. Known infection with human immunodeficiency virus (HIV), or an active infection with hepatitis B or hepatitis C.
Must not have an active symptomatic fungal, bacterial or viral infection, including human immunodeficiency virus (HIV) or Hepatitis A, B, or C
Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy. Known infection with HIV, or an active infection with hepatitis B or hepatitis C.
Uncontrolled viral, bacterial, or fungal infections (human immunodeficiency virus [HIV] infection permitted if viral load undetectable)
Active and clinically significant bacterial, fungal or viral infection\r\n* Known infections with hepatitis B (HBV) or hepatitis C (HCV)\r\n* Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness not controlled (with undetectable viral load) on highly active antiretroviral therapy (HAART) therapy; patients on HAART with undetectable viral loads may be eligible per principal investigator (PI) judgment
Uncontrolled bacterial, fungal, or viral infections including HIV - chronic asymptomatic viral hepatitis is allowed
Active and uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy. Known infection with human immunodeficiency virus (HIV), or an active infection with hepatitis B or hepatitis C.
The participant has an active fungal, bacterial, and/or known viral infection including human immunodeficiency virus (HIV) or viral (A, B, or C) hepatitis (screening is not required).
The participant has an active fungal, bacterial, and/or known severe viral infection including human immunodeficiency virus (HIV) or viral (A, B, or C) hepatitis (screening is not required).
Patients with other viral infections are ineligible:\r\n* Known to have acute or chronic active hepatitis B or hepatitis C infection\r\n* Known to have human immunodeficiency virus (HIV) infection\r\n* Prior therapy with viral-based tumor vaccine\r\n* Received live vaccine within 28 days prior to enrollment
Have an active fungal, bacterial and/or known viral infection including human immunodeficiency virus or viral (A, B, or C) hepatitis (screening is not required).
Presence of fungal, bacterial, viral, or other infection that is uncontrolled or requiring IV antimicrobials for management; simple urinary tract infection (UTI) and uncomplicated bacterial pharyngitis are permitted if responding to active treatment; known history of infection with human immunodeficiency virus (HIV) or hepatitis B (hepatitis B surface antigen [HBsAg] positive) or hepatitis C virus (anti hepatitis C virus [HCV] positive); a history of hepatitis B or hepatitis C is permitted if the viral load is undetectable per quantitative PCR and/or nucleic acid testing
Presence of any serious illnesses, serious medical conditions, serious medical history, active bacterial or viral infections including hepatitis B or C, or known to be HIV positive.
Uncontrolled bacterial, fungal or viral infections including human immunodeficiency virus (HIV)-1/2 or active hepatitis C/B - chronic asymptomatic viral hepatitis is allowed
Uncontrolled bacterial or viral infections, or known human immunodeficiency virus (HIV), hepatitis B, or hepatitis C infection
Uncontrolled bacterial, fungal or viral infections including human immunodeficiency virus (HIV)-1/2 or active hepatitis C/B - chronic asymptomatic viral hepatitis is allowed
Active systemic illness (infection including viral illnesses such as hepatitis and human immunodeficiency virus [HIV])
Have an active fungal, bacterial, and/or known viral infection including human immunodeficiency virus (HIV) or viral (A, B, or C) hepatitis
Active systemic fungal, bacterial, viral, or other infection, unless disease is under treatment with anti-microbials and/or controlled or stable (e.g. if specific, effective therapy is not available/feasible or desired [e.g. chronic viral hepatitis, human immunodeficiency virus (HIV)]); patient needs to be clinically stable as defined as being afebrile and hemodynamically stable for 24-48 hours
Uncontrolled bacterial or viral infections, or known human immunodeficiency virus (HIV), hepatitis B or C infection
Active systemic fungal, bacterial, viral, or other infection, unless disease is under treatment with anti-microbials and/or controlled or stable (e.g. if specific, effective therapy is not available/feasible or desired [e.g. chronic viral hepatitis, human immunodeficiency virus (HIV)]); patient needs to be clinically stable as defined as being afebrile and hemodynamically stable for 24-48 hours prior to study day 0, unless fever is thought to be secondary to the underlying hematologic disease
Active uncontrolled infection; presence of latent or medication-controlled human immunodeficiency virus (HIV) and/or viral hepatitis is allowed
CERITINIB EXCLUSION CRITERIA: Known active infection (bacterial, fungal, viral including human immunodeficiency virus [HIV] positivity)
Have active and clinically relevant bacterial, fungal, or viral infection, including known Hepatitis A, B, or C or human immunodeficiency virus (HIV) (testing not required)
Uncontrolled bacterial or viral infections, or known HIV, hepatitis B or C infection
Uncontrolled infection, defined as an infection which has not resolved spontaneously or does not show evidence of significant resolution after initiating appropriate therapy, excluding chronic asymptomatic viral infections (e.g., human papillomavirus [HPV], BK virus, hepatitis C virus [HCV], etc.)
Patients with active uncontrolled life threatening infection (s) from viral, bacterial, fungal or other organisms will be excluded; patients with human immunodeficiency virus (HIV) infection will be excluded
Active or symptomatic infection including human immunodeficiency virus (HIV), viral hepatitis or chronic liver disease
Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy. Known infection with HIV, or an active infection with hepatitis B or hepatitis C
Uncontrolled bacterial, fungal or viral infections including human immunodeficiency virus (HIV)-1/2 or active hepatitis C/B - chronic asymptomatic viral hepatitis is allowed
Patients with uncontrolled bacterial, viral or fungal infections including diagnosis of acute viral hepatitis (defined as any active infection with hepatitis A or a new diagnosis of hepatitis B or C within 24 weeks of transplant)
Must not have an active symptomatic fungal, bacterial or viral infection, including human immunodeficiency virus (HIV) or Hepatitis A, B, or C
Active symptomatic fungal, bacterial and/or viral infection including active HIV or viral hepatitis.
Active systemic fungal, bacterial, viral, or other infection, unless disease is under treatment with anti-microbials, and/or controlled or stable (e.g. if specific, effective therapy is not available/feasible or desired [e.g. known chronic viral hepatitis, human immunodeficiency virus (HIV)]); patient needs to be clinically stable as defined as being afebrile and hemodynamically stable for 24 hours; patients with fever thought to be likely secondary to leukemia are eligible
Uncontrolled bacterial, fungal or viral infections including HIV-1/2 or active hepatitis C/B - chronic asymptomatic viral hepatitis is allowed
Participant has an active systemic fungal and/or known viral infection (for example, human immunodeficiency virus antibodies, hepatitis B surface antigen or hepatitis C antibodies)
Other viral infections:\r\n* Known to have acute or chronic active hepatitis B or hepatitis C infection\r\n* Known to have human immunodeficiency virus (HIV) infection\r\n* Prior therapy with viral-based tumor vaccine\r\n* Received live vaccine within 28 days prior to enrollment
Active infection (e.g., human immunodeficiency virus [HIV] or viral hepatitis) or other medical condition that would make prednisone/prednisolone corticosteroid) use contraindicated
Other viral infections\r\n* Known to have acute or chronic active hepatitis B or hepatitis C infection\r\n* Known to have human immunodeficiency virus (HIV) infection\r\n* Prior therapy with viral-based tumor vaccine\r\n* Received live vaccine within 28 days prior to enrollment
Have known active fungal, bacterial, and/or viral infection, including human immunodeficiency virus (HIV) or hepatitis virus (A,B, or C).
Have active bacterial, fungal, and/or known viral infection (for example, human immunodeficiency virus [HIV] antibodies, hepatitis B surface antigen [HBSAg], or hepatitis C antibodies). Screening is not required for enrollment.
Active systemic fungal, bacterial, viral, or other infection, unless disease is under treatment with anti-microbials and/or controlled or stable (e.g. if specific, effective therapy is not available/feasible or desired [e.g. chronic viral hepatitis, human immunodeficiency virus (HIV)]); patient needs to be clinically stable as defined as being afebrile and hemodynamically stable for 24 hours; patients with fever thought to be likely secondary to leukemia are eligible
The participant has a known active fungal, bacterial, or viral infection including human immunodeficiency virus (HIV) or viral (A, B, or C) hepatitis (screening is not required).
Active symptomatic fungal, bacterial and/or viral infection including evidence of infection with human immunodeficiency virus (HIV)
Active human immunodeficiency virus (HIV) or hepatitis B or C with positive viral load, requiring anti-viral therapy
Active or chronic systemic infection, including viral hepatitis, human immunodeficiency virus (HIV), mycobacteria, tuberculosis (TB), or other opportunistic infections
Have active bacterial, fungal, and/or known viral infection (for example, human immunodeficiency virus [HIV] antibodies, hepatitis B surface antigen [HBSAg], or hepatitis C antibodies) Screening is not required for enrollment
Uncontrolled bacterial or viral infections - chronic asymptomatic viral hepatitis is allowed
Uncontrolled bacterial, fungal or viral infections including human immunodeficiency virus (HIV) - chronic asymptomatic viral hepatitis is allowed
Presence of an active acute or chronic infection, including urinary tract infection, human immunodeficiency virus (HIV) or viral hepatitis HIV patients are excluded based on immunosuppression which may render them unable to respond to the vaccine; patients with chronic hepatitis are excluded because of concern that hepatitis could be exacerbated by the injections; if clinically indicate HIV/viral hepatitis testing will be performed to confirm status
Currently known uncontrolled bacterial, viral, fungal, HIV, hepatitis B, or hepatitis C infection
Active, uncontrolled bacterial, fungal or viral infection, including hepatitis B, hepatitis C, known human immunodeficiency virus or acquired immunodeficiency syndrome related illness.
Patients with previously known infection with human immunodeficiency virus (HIV) or active viral hepatitis are ineligible; (diagnostic testing for these infections will be done only if clinically indicated)
Have known fungal, bacterial, and/or viral infection, including human immunodeficiency virus (HIV) or hepatitis virus (B or C);
Have an active fungal, bacterial, and/or known viral infection including human immunodeficiency virus (HIV) or viral (A, B, or C) hepatitis (screening is not required).
Must not have an active symptomatic fungal, bacterial or viral infection, including human immunodeficiency virus (HIV) or Hepatitis A, B, or C.
Known active fungal, bacterial, and/or known viral infection including human immunodeficiency (HIV) or viral (A, B, or C) hepatitis (screening is not required).;
Active systemic fungal, bacterial, viral, or other infection, unless disease is under treatment with anti-microbials and/or controlled or stable (e.g. if specific, effective therapy is not available/feasible or desired [e.g. chronic viral hepatitis, human immunodeficiency virus (HIV)]); patient needs to be clinically stable as defined as being afebrile and hemodynamically stable for 24 hours; patients with fever thought to be likely secondary to leukemia are eligible
Have a known active fungal, bacterial, and/or known viral infection including human immunodeficiency (HIV) or viral (A, B, or C) hepatitis (screening is not required)
Have an active systemic fungal and/or known viral infection (for example, human immunodeficiency virus antibodies, hepatitis B surface antigen, or hepatitis C antibodies)
Active infection (such as human immunodeficiency virus [HIV] or viral hepatitis) or other medical condition that would make corticosteroid use contraindicated
Evidence of any active uncontrolled infection (bacterial, viral or fungal) or evidence of natural exposure to hepatitis B, hepatitis C or human immunodeficiency virus (HIV) without demonstration of polymerase chain reaction (PCR) negativity for said virus; vaccination to hepatitis B is not an exclusion criterion
Current or previous history of liver, gastrointestinal, hematopoietic, cardiac or renal disease, viral, bacterial, atypical or fungal infections of any organ system and human immunodeficiency virus (HIV) infection
Active systemic illness (infection including viral illnesses such as hepatitis and human immunodeficiency virus [HIV])
Have an active fungal, bacterial, and/or known viral infection, including human immunodeficiency virus (HIV) or viral (B or C) hepatitis.
Known positivity for human immunodeficiency virus (HIV)
Subject has known positivity for human immunodeficiency virus
Known history of human immunodeficiency virus (HIV)-positivity
Known human immunodeficiency virus (HIV) positivity
Known HIV positivity
HER-2 positivity
Known history of human immunodeficiency virus (HIV) sero-positivity
Known human immunodeficiency virus (HIV) positivity
Human immunodeficiency virus (HIV) positivity or evidence of active hepatitis C virus.
EXCLUSION - PROCUREMENT: Known primary immune deficiency or human immunodeficiency virus (HIV) positivity
Research participants who have confirmed human immunodeficiency virus (HIV) positivity within 4 weeks of enrollment
Known human immunodeficiency virus (HIV)-positivity
Known human immunodeficiency virus (HIV) positivity
History of positivity for human immunodeficiency virus
Patients should have no evidence, as listed below, of being immunocompromised:\r\n• Human immunodeficiency virus (HIV) positivity due to the potential for decreased tolerance and risk for severe side effects\r\n• Hepatitis B or C positivity
Known human immunodeficiency virus (HIV) positivity
Known human immunodeficiency virus (HIV)-positivity
Known positivity for human immunodeficiency virus (HIV)
AT THE TIME OF PROCUREMENT: Known human immunodeficiency virus (HIV) positivity
AT THE TIME OF INFUSION: HIV positivity
Human immunodeficiency virus (HIV) positivity
PROCUREMENT: Known human immunodeficiency virus (HIV) positivity
Known history of human immunodeficiency virus (HIV) positivity
Known positivity for human immunodeficiency virus (HIV); Note: baseline testing for HIV is not required
Known human immunodeficiency virus (HIV)-positivity
Known human immunodeficiency virus (HIV)-positivity
Known positivity for human immunodeficiency virus (HIV)
Known human immunodeficiency virus (HIV) positivity
Known human immunodeficiency virus (HIV) positivity
Known human immunodeficiency virus (HIV) positivity
Known HIV positivity
Patients with documented human immunodeficiency virus (HIV) positivity
Known human immunodeficiency virus (HIV)-positivity
Known human immunodeficiency virus (HIV)-positivity
Known positivity for human immunodeficiency virus (HIV)
Subject has known positivity for human immunodeficiency virus (HIV)
Patients with chronic viral illnesses such as human immunodeficiency virus (HIV)-positivity and active hepatitis B or C are ineligible
Patients with known positivity for human immunodeficiency virus (HIV) or hepatitis C
Known human immunodeficiency virus (HIV)-positivity or other history of immunodeficiency disorder
Known human immunodeficiency virus (HIV) positivity
Known human immunodeficiency virus (HIV)-positivity
With human immunodeficiency virus (HIV)-positivity or active infectious hepatitis
Human immunodeficiency virus (HIV) positivity
Prior history of human immunodeficiency virus (HIV) positivity or known history of hepatitis B or C
Known human immunodeficiency virus (HIV) positivity
Known HIV positivity
Known human immunodeficiency virus (HIV) positivity
Human immunodeficiency virus (HIV) 1 or 2 positivity
Known human immunodeficiency virus (HIV)-positivity
Patients must not have known human immunodeficiency virus (HIV), hepatitis B or C positivity
Known human immunodeficiency virus, viral hepatitis, or tuberculosis positivity
Known human immunodeficiency virus (HIV) positivity
Known human immunodeficiency virus (HIV) positivity
Know human immunodeficiency virus (HIV) positivity
Patients with known positivity for human immunodeficiency virus (HIV) or active hepatitis B or C; baseline testing is not required
Known human immunodeficiency virus (HIV)-positivity AND actively being treated with highly active anti-retroviral therapy (HAART)
AT THE TIME OF PROCUREMENT: Known human immunodeficiency virus (HIV) positivity
Known human immunodeficiency virus (HIV) positivity
Known prior positivity for active human immunodeficiency virus (HIV) or infectious hepatitis, type B or C
Human immunodeficiency virus (HIV) positivity
Known positivity for HIV.
Human immunodeficiency virus (HIV) Positivity
Human immunodeficiency virus (HIV) 1 or 2 positivity
Patients with known positivity for human immunodeficiency virus (HIV) or hepatitis B/C
Known human immunodeficiency virus (HIV)-positivity; therapy with immunosuppressive agents
Known human immunodeficiency virus (HIV) positivity
Known human immunodeficiency virus (HIV)-positivity
Known history of human immunodeficiency virus (HIV) sero-positivity
Known human immunodeficiency virus (HIV) positivity
Known HIV positivity (testing not required).
Known Human Immunodeficiency Virus (HIV) positivity or active infectious hepatitis A, B or C
Known human immunodeficiency virus (HIV) positivity
Known positivity for human immunodeficiency virus (HIV); note: baseline testing for HIV is not required
Known human immunodeficiency virus (HIV) positivity
Known human immunodeficiency virus (HIV) positivity
Known positivity for human immunodeficiency virus (HIV) or active hepatitis B or C
Known human immunodeficiency virus (HIV) positivity
Patients with a known confirmed diagnosis of human immunodeficiency virus (HIV) infection or active viral hepatitis
Known human immunodeficiency virus or active hepatitis C viral infection
Known history of human immunodeficiency virus infection (HIV) or hepatitis C or active hepatitis B infection, unless the patient was diagnosed >10 years prior to enrollment and no evidence of active liver disease.
EXCLUSION CRITERIA FOR SECOND-LINE THERAPY: Active severe infection, or known chronic infection with human immunodeficiency virus (HIV) or hepatitis B virus
EXCLUSION CRITERIA FOR THIRD-LINE THERAPY: Active severe infection, or known chronic infection with human immunodeficiency virus (HIV) or hepatitis B virus
Known human immunodeficiency virus (HIV) or known active hepatitis B virus or hepatitis C virus infection
New York Heart Association (NYHA) stage III/IV congestive heart failure, arrhythmias not adequately controlled, active infections, or other significant co-morbidities [e.g. active central nervous system metastases and/or carcinomatous meningitis, active infection requiring systemic therapy, history of human immunodeficiency virus (HIV) infection, or active Hepatitis B or Hepatitis C.
Known ongoing or active systemic infection, active hepatitis B or C virus infection
No known human immunodeficiency virus (HIV) positive, or active hepatitis infection
Known active hepatitis B infection, active hepatitis C infection or known human immunodeficiency virus (HIV) carrier
Patients who have active infection including known human immunodeficiency virus (HIV) infection
Active hepatitis or human immunodeficiency virus infection
Patients with human immunodeficiency virus (HIV) infection, or active hepatitis B or C virus infection will be excluded
PHASE II EXCLUSION CRITERIA: Patients with human immunodeficiency virus (HIV) infection, or active hepatitis B or C virus infection will be excluded
Ongoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive
Serious concurrent illness or clinically-relevant active infection, including, but not limited to the following:\r\n* Known active hepatitis B or C\r\n* Known human immunodeficiency virus (HIV) infection\r\n* Varicella-zoster virus (shingles)\r\n* Cytomegalovirus infection\r\n* Any other known concurrent infectious disease, requiring IV antibiotics with 2 weeks of study enrollment
Active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive
Ongoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive
Known history of human immunodeficiency virus infection or current chronic/active hepatitis B or C infection.
Ongoing or active infection, known human immunodeficiency virus positive, active hepatitis B or C infection.
Patients must not have known human immunodeficiency virus (HIV) infection or active hepatitis B or C infections
Known active human immunodeficiency virus (HIV) or hepatitis B or C infection
Known human immunodeficiency virus or active hepatitis B or C viral infection
Known history of human immunodeficiency virus (HIV) or active hepatitis C virus or active hepatitis B virus infection or any uncontrolled active systemic infection
Patients with known infection with human immunodeficiency virus (HIV) or active hepatitis B or C
Has active human immunodeficiency virus infection that is uncontrolled (increasing plasma HIV RNA viral load) with medication, or has an active hepatitis B or C infection
Known infection caused by human immunodeficiency virus (HIV) or active hepatitis B or C
Active uncontrolled infection at study enrollment including known diagnosis of human immunodeficiency virus or chronic active hepatitis B or C infection
Known history of human immunodeficiency virus (HIV) seropositivity, hepatitis C virus, acute or chronic active hepatitis B infection, or other serious chronic infection requiring ongoing treatment; patients receiving prophylactic antibiotics (e.g., for prevention of urinary tract infection or chronic obstructive pulmonary disease) are eligible
Ongoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive
Known or active human immunodeficiency virus (HIV) infection or active hepatitis B or C viral infection
Patients with known infection with human immunodeficiency virus (HIV) or active hepatitis B or C
Active severe infection, or known chronic infection with human immunodeficiency virus (HIV) or hepatitis B virus (testing not required prior to enrollment)\r\n* Patients with chronic hepatitis C virus may be enrolled if there is no clinical/laboratory evidence of cirrhosis AND the patient’s liver function tests fall within the parameters
Known evidence of an active infection requiring systemic therapy such as human immunodeficiency virus (HIV), active hepatitis, or fungal infection.
Patients with a known chronic immunocompromised state, human immunodeficiency virus (HIV) infection, or active hepatitis B or C infection
Serious concurrent illness or clinically-relevant active infection, including, but not limited to the following:\r\n* Known active hepatitis B or C\r\n* Known human immunodeficiency virus (HIV) infection\r\n* Varicella-zoster virus (shingles)\r\n* Cytomegalovirus infection\r\n* Any other known concurrent infectious disease, requiring IV antibiotics within 2 weeks of study enrollment
Known to have acute or chronic active hepatitis B infection, hepatitis C infection, or known to have human immunodeficiency virus (HIV) infection
Active uncontrolled infection at study enrollment including known diagnosis of human immunodeficiency virus or chronic active hepatitis B or C infection
Known history of human immunodeficiency virus (HIV) infection, active infection with hepatitis B virus or hepatitis C virus, or any uncontrolled active systemic infection
Infection with human immunodeficiency virus (HIV) and/or chronic/active infection with hepatitis B virus or hepatitis C virus
Known history of human immunodeficiency virus infection or an active hepatitis B or C virus infection (exception: this criteria does not apply to patients with cervical/anal tumours enrolling in Cohort 6)
Ongoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive
Known history of human immunodeficiency virus (HIV) or active hepatitis C virus or active hepatitis B virus infection or any uncontrolled active systemic infection
Known active infection with human immunodeficiency virus (HIV), hepatitis B or C viruses (screening not required)
Known positive test(s) for human immunodeficiency virus infection, hepatitis C virus, acute or chronic active hepatitis B infection
Ongoing or active known infection, including human immunodeficiency virus (HIV) infection
Known active acute or chronic infection including urinary tract infection, human immunodeficiency virus (HIV) or viral hepatitis
Known human immunodeficiency virus (HIV) infection or active hepatitis A, B or C
Ongoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive
Known positive test(s) for human immunodeficiency virus infection, hepatitis C virus, acute or chronic active hepatitis B infection
Ongoing or active systemic infection, known active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive
Active hepatitis A, B, or C virus infection, or known human immunodeficiency virus (HIV) positive
Ongoing or active systemic infection, known active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive
Ongoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive
Ongoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positivity
Known ongoing or known active systemic infection, known active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive
Known history of human immunodeficiency virus (HIV) or active hepatitis C virus or active hepatitis B virus infection or any uncontrolled active systemic infection
Active and uncontrolled infection including but not limited to known infection with human immunodeficiency virus (HIV), active hepatitis B, or hepatitis C
Active infection requiring treatment, known immunosuppressive disease, active systemic autoimmune diseases such as lupus, receipt of systemic immunosuppressive therapy, human immunodeficiency virus (HIV) infection, hepatitis B or hepatitis C
Known positive for human immunodeficiency virus-1 (HIV-1), or active infection with hepatitis-B or -C
Active severe infection, or known chronic infection with human immunodeficiency virus (HIV), hepatitis B virus; patients with chronic hepatitis C virus may be enrolled if there is no clinical/laboratory evidence\r\nof cirrhosis AND the patient’s liver function tests fall within the parameters set
Human immunodeficiency virus (HIV) infection, active hepatitis B or C infection, or evidence of liver cirrhosis
A known history of human immunodeficiency virus (HIV) seropositivity, hepatitis C virus, acute or chronic active hepatitis B infection, or other serious chronic infection requiring ongoing treatment
History of human immunodeficiency virus (HIV), or known active hepatitis B or C infection.
Ongoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus positive.
Subjects with known active hepatitis B or C infection, or hepatobiliary disease, or known history of immunodeficiency virus infection.
Known positive test result for human immunodeficiency virus or active hepatitis B or C virus infection
Has known human immunodeficiency virus (HIV) infection, or active hepatitis B or C infection based on positive tests during Screening
Chronic hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive, that might affect host immunity
Ongoing, active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive
RENAL & BLADDER: Known evidence of an active infection requiring systemic therapy such as human immunodeficiency virus (HIV), active hepatitis, or fungal infection
Active systemic infection requiring treatment, including any human immunodeficiency virus (HIV) infection or toxoplasmosis
Evidence of any of the following conditions per subject self-report or medical chart review\r\n* Any prior invasive malignancy within 5 years of enrollment that may affect outcome of study\r\n* Any non-invasive malignancy not treated with curative intent or with known active disease within 5 years before enrollment that may affect outcome of study\r\n* Major surgery or significant traumatic injury occurring within 4 weeks before enrollment\r\n* Active infection with hepatitis B virus or hepatitis C virus\r\n* Known infection with human immunodeficiency virus (HIV)\r\n* Active infection requiring IV anti-infective therapy
Patients with known active hepatitis B or C or human immunodeficiency virus (HIV) infection or with history of tuberculosis
Known active or chronic human immunodeficiency virus (HIV) or hepatitis C virus (HCV) infection, or positive hepatitis B (Hep B) surface antigen; prior hepatitis infection that has been treated with highly effective therapy with no evidence of residual infection and with normal liver function (ALT, AST, total and direct bilirubin =< ULN) is allowed
Known active human immunodeficiency virus (HIV) or hepatitis A, B, or C virus infection
Active severe infection, or known chronic infection with human immunodeficiency virus (HIV) or hepatitis B virus; patients with chronic hepatitis C virus may be enrolled if there is no clinical/laboratory evidence of cirrhosis AND the patient’s liver function tests fall within the parameters set above
Ongoing or active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive
Known active hepatitis B infection, known active hepatitis C infection, or known human immunodeficiency virus (HIV) carrier
Patients with active severe infection; known infection with human immunodeficiency virus (HIV), hepatitis B virus, hepatitis C virus, or severe concurrent illness will be excluded from the study; HIV-positive patients on combination antiretroviral therapy are ineligible
Known human immunodeficiency virus (HIV) infection or known history of active hepatitis B or C infection
Patients with active severe infection; known infection with human immunodeficiency virus (HIV), hepatitis B virus, hepatitis C virus, or severe concurrent illness
Known infection with human immunodeficiency virus, or active hepatitis B or C, or other active clinically relevant liver disease.
Subjects with known infection with human immunodeficiency virus (HIV) or active hepatitis B or C.
Patients with known infection with human immunodeficiency virus (HIV) or active hepatitis B or C
Known history of human immunodeficiency virus (HIV) seropositivity, acute or chronic active hepatitis B or C infection, or other serious chronic infection requiring ongoing treatment
Ongoing or active infection, known human immunodeficiency virus (HIV) positive, active hepatitis B or C infection.
Has evidence of interstitial lung disease, active non-infectious pneumonitis, a known additional malignancy that is progressing or requires active treatment, an active infection requiring intravenous systemic therapy, an active autoimmune disease that has required systemic therapy, a known Human Immunodeficiency Virus (HIV), Hepatitis B (HBV), or Hepatitis C (HCV) infection
Known Human Immunodeficiency Virus (HIV) infection or active hepatitis A, B, or C
Known active hepatitis B or C, or human immunodeficiency virus (HIV) infection
Known history of human immunodeficiency virus (HIV), or known active hepatitis A, B, or C infection;
Known history of human immunodeficiency virus or active infection with hepatitis virus or any uncontrolled active systemic infection.
Active viral hepatitis or active human immunodeficiency virus infection
Patient has a known history of human immunodeficiency virus (HIV) (testing not mandatory), active hepatitis B or C infection
Patients with a known confirmed diagnosis of human immunodeficiency virus (HIV) infection or active viral hepatitis (B or C)
Ongoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive
Patients with active infections including uncontrolled human immunodeficiency virus (HIV) infection, active hepatitis B, C, or any other symptomatic systemic infection requiring active therapy will be excluded from study
Human immunodeficiency virus (HIV) positive or active infection requiring treatment (except for hepatitis virus)
Known human immunodeficiency virus (HIV) infection, active chronic hepatitis B or C, or life-threatening illnesses unrelated to cancer.
Active or chronic infection with hepatitis C virus (HCV) or hepatitis B virus or known active or chronic infection with human immunodeficiency virus; prior hepatitis infection that has been treated with highly effective therapy with no evidence of residual infection (including undetectable viral loads while on antiviral therapy) and with normal liver function (ALT, AST, total and direct bilirubin =< ULN) is allowed
Active infection including tuberculosis, hepatitis B or C, or human immunodeficiency virus.
Active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive
The participant has active infection requiring systemic therapy, including active tuberculosis or known history of infection with the human immunodeficiency virus (HIV 1/2 antibodies), or hepatitis B (e.g., HBsAg reactive) and/or C virus (e.g., HCV RNA [qualitative] is detected).
Active or chronic infection with hepatitis C virus (HCV) or hepatitis B virus or known active or chronic infection with human immunodeficiency virus.
Clinically active infection as judged by the treating investigator (? Grade 2 by CTCAE v4) including known human immunodeficiency virus (HIV) infection or chronic hepatitis B or C
Active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive.
Ongoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive
Subjects with known infection with human immunodeficiency virus (HIV) or active hepatitis B or C.
Known active uncontrolled human immunodeficiency virus (HIV) or hepatitis C infection
Comorbidities or prior conditions:\r\n* Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial\r\n* Prior organ transplantation including allogenic stem-cell transplantation\r\n* Known additional malignancy that is progressing or requires active treatment; exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy\r\n* Known history of active TB (Tuberculosis)\r\n* Known history of human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome\r\n* Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at screening or positive serologies indicating prior infection\r\n* Active infection requiring systemic therapy\r\n* Has evidence of interstitial lung disease or active, non-infectious pneumonitis\r\n* Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (>= New York Heart Association Classification class II), or serious cardiac arrhythmia requiring medication
Known human immunodeficiency virus (HIV) or active hepatitis B or C viral infection
Subjects with known infection with human immunodeficiency virus (HIV) or active hepatitis B or C.
Known history of human immunodeficiency virus or active hepatitis C virus or active hepatitis B virus infection or any uncontrolled active systemic infection requiring intravenous antibiotics
Active hepatitis B or C virus infection, or known human immunodeficiency virus(HIV) positive
A known confirmed diagnosis of human immunodeficiency virus (HIV) infection or active viral hepatitis
Known human immunodeficiency virus (HIV) or active hepatitis B or C infection
Ongoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus positive.
Known active infection, or on antiretroviral therapy for human immunodeficiency virus (HIV) disease or positive test for chronic hepatitis B or C infection
Active severe infection, or known chronic infection with human immunodeficiency virus (HIV) or hepatitis B virus\r\n* Patients with chronic hepatitis C virus may be enrolled if there is no clinical/laboratory evidence of cirrhosis AND the patient’s liver function tests fall within the parameters set in inclusion criteria number 8c, “hepatic function”
Known Human immunodeficiency virus (HIV) infection or active hepatitis A, B, or C
Active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive
Patients with known active viral hepatitis or known human immunodeficiency virus (HIV) infection
Known positive test(s) for human immunodeficiency virus infection, hepatitis C virus, acute or chronic active hepatitis B infection
Known positive test(s) for human immunodeficiency virus infection, hepatitis C virus, chronic active hepatitis B infection
Known history of human immunodeficiency virus or active hepatitis C virus or active hepatitis B virus infection or any uncontrolled active systemic infection requiring intravenous antibiotics
Active severe infection, or known chronic infection with human immunodeficiency virus (HIV), hepatitis B virus\r\n* Patients with chronic hepatitis C virus may be enrolled if there is no clinical/laboratory evidence of cirrhosis AND the patient’s liver function tests fall within the parameters set
Known active infection with human immunodeficiency virus (HIV), hepatitis B or C
Known history of human immunodeficiency virus (HIV) or active hepatitis C virus or active hepatitis B virus infection or any uncontrolled active systemic infection
Known ongoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive
Has known, previously diagnosed human immunodeficiency virus infection or active chronic hepatitis B or C.
Ongoing or active systemic infection, history of hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive
Active hepatitis B infection, active hepatitis C infection or known human immunodeficiency virus (HIV) carrier
Known history of human immunodeficiency virus or active infection with hepatitis C virus or hepatitis B virus or any uncontrolled active systemic infection
Ongoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive
Known ongoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive
Known human immunodeficiency virus (HIV) infection or active hepatitis B virus or hepatitis C virus infection.
Known human immunodeficiency virus (HIV) or active hepatitis B or C infection
Active severe infection, or known chronic infection with human immunodeficiency virus (HIV) or hepatitis B virus
Known active human immunodeficiency virus (HIV) infection, hepatitis B or C
Known infection with human immunodeficiency virus (HIV) or active hepatitis B or C
Active hepatitis B infection, active hepatitis C infection or known human immunodeficiency virus (HIV) carrier
Acute hepatitis, known human immunodeficiency virus (HIV), or active uncontrolled infection
No infection with human immunodeficiency virus (HIV) and no active infection with hepatitis B and no active or chronic infection with hepatitis C
No human immunodeficiency virus (HIV) infection, active hepatitis B infection, or active hepatitis C infection
Current evidence or previous medical history of (ie, any absolute risk of latent infection) hepatitis B or C, any active hepatitis, or human immunodeficiency virus (HIV) infection. Active clinically serious infections > CTCAE Grade 2.
Ongoing or active known infection, including human immunodeficiency virus (HIV) infection or bleeding
Known positive test for human immunodeficiency virus infection, hepatitis C virus, acute or chronic hepatitis B infection, or any co-morbid disease that would increase risk of toxicity.
Known history of human immunodeficiency virus (HIV) or active hepatitis C virus or active hepatitis B virus infection or any uncontrolled active systemic infection
Known evidence of an active infection requiring systemic therapy such as human immunodeficiency virus (HIV), active hepatitis, or fungal infection
Known history of human immunodeficiency virus (HIV) or active hepatitis C Virus or active hepatitis B virus infection or any uncontrolled active systemic infection
Human immunodeficiency virus (HIV) infection; active hepatitis B infection; active hepatitis C infection
Active infection requiring systemic therapy, known human immunodeficiency virus infection, or positive test for hepatitis B active infection or hepatitis C active infection.
Known active infection with human immunodeficiency virus (HIV), hepatitis A, B, or C
Known positive status for human immunodeficiency virus (HIV) infection; known active hepatitis B or hepatitis C infection
Known active hepatitis B/C or HIV (human immunodeficiency virus) infection
Ongoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive
Human Immunodeficiency Virus (HIV) infection
Human immunodeficiency virus (HIV) infection
Human immunodeficiency virus (HIV) infection
Infection with human immunodeficiency virus (HIV)
Patients may not have diagnosed human immunodeficiency virus (HIV)
Human immunodeficiency virus (HIV)
Negative human immunodeficiency virus (HIV) antibody.
Human immunodeficiency virus (HIV 1/2)
Human immunodeficiency virus (HIV)
Human Immunodeficiency Virus (HIV) infection
Patients who have a history of human immunodeficiency virus (HIV) disease
History of human immunodeficiency virus (HIV) infection
AUTOLOGOUS APHERESIS: History of human immunodeficiency virus (HIV) infection
Human immunodeficiency virus (HIV) infection.
Subject has any history of human immunodeficiency virus (HIV) or immunodeficiency at Screening.
History of human immunodeficiency virus (HIV);
Subjects must not have a confirmed human immunodeficiency virus (HIV) infection.
Human immunodeficiency virus (HIV) infection.
Negative human immunodeficiency virus (HIV) antibody.
Active human immunodeficiency virus (HIV) infection
Uncontrolled human immunodeficiency virus (HIV) infection
Uncontrolled human immunodeficiency virus (HIV)
Human immunodeficiency virus (HIV) infection
Documented human immunodeficiency virus (HIV)-infection
Infection with human immunodeficiency virus (HIV)
Human immunodeficiency virus (HIV) infection
Human immunodeficiency virus (HIV) infection
Active human immunodeficiency virus (HIV) infection or known human immunodeficiency virus (HIV) positive serology
Subjects must not have a history of human immunodeficiency virus (HIV) infection
Diagnosed immunodeficiency, eg, human immunodeficiency virus (HIV)
Patients with human immunodeficiency virus (HIV) are not permitted to enroll
Patients with human immunodeficiency virus (HIV) infection are excluded from the study
DONOR: Human immunodeficiency virus (HIV) negative
Human immunodeficiency virus (HIV) infection with CD4 count < 240
Human immunodeficiency virus (HIV) infection
Human immunodeficiency virus (HIV) infection
Human immunodeficiency virus (HIV) infection
Human immunodeficiency virus (HIV) infection
History of human immunodeficiency virus (HIV) infection
Human immunodeficiency virus (HIV) infection
Known human immunodeficiency virus (HIV) disease (requires negative test for clinically suspected HIV infection)
Human immunodeficiency virus (HIV)-negative
Human immunodeficiency virus (HIV) infection
Patients must be negative for human immunodeficiency virus (HIV)
Human immunodeficiency virus (HIV) infection
Human immunodeficiency virus (HIV) infection
RECIPIENT: Human immunodeficiency virus (HIV) infection
DONOR: Human immunodeficiency virus (HIV) negative
Human immunodeficiency virus (HIV) infection
Human immunodeficiency virus (HIV) infection
Human immunodeficiency virus (HIV) negative
DONOR: Infection with human immunodeficiency virus (HIV)
Human immunodeficiency virus (HIV) negative
Human immunodeficiency virus (HIV) infection
History of human immunodeficiency virus (HIV) infection
Human immunodeficiency virus (HIV) negative
Human immunodeficiency virus (HIV) infection
Human immunodeficiency virus (HIV) negative
Human immunodeficiency virus (HIV) infection
Subjects cannot have an active immunodeficiency disorder, e.g. human immunodeficiency virus (HIV)
History of or active human immunodeficiency virus (HIV) infection at the time of screening
Human immunodeficiency virus (HIV) infection
History of human immunodeficiency virus (HIV) infection
History of human immunodeficiency virus (HIV) infection
Confirmed human immunodeficiency virus (HIV) infection.
Patients with human immunodeficiency virus (HIV) infection are ineligible
Human immunodeficiency virus (HIV) negative
History of human immunodeficiency virus (HIV) infection
Human immunodeficiency virus (HIV) infection
Immunodeficiency states including human immunodeficiency virus (HIV) infection
DONOR: Infection with human immunodeficiency virus (HIV)
Human immunodeficiency virus (HIV) infection.
Human immunodeficiency virus (HIV)-infection
History of human immunodeficiency virus (HIV)
Infection with human immunodeficiency virus (HIV)
Participants must be human immunodeficiency virus (HIV) negative =< 6 months prior to screening
Human immunodeficiency virus (HIV) antibody
Patient Human Immunodeficiency Virus (HIV) infection
Human Immunodeficiency Virus (HIV) infection
No infection with human immunodeficiency virus (HIV)
History of Human Immunodeficiency Virus (HIV)
Human immunodeficiency virus (HIV) negative
Negative human immunodeficiency virus (HIV) antibody
Patients with active and uncontrolled human immunodeficiency virus (HIV) infection will be excluded; however, patients with well controlled HIV infection will be considered
Human immunodeficiency virus (HIV) infection
Have a history or current evidence of human immunodeficiency virus (HIV) infection.
Documented human immunodeficiency virus (HIV) infection
Human immunodeficiency virus (HIV)
Human immunodeficiency virus (HIV)
Human immunodeficiency virus (HIV)
Uncontrolled human immunodeficiency virus (HIV)
Human immunodeficiency virus (HIV) infection or immunodeficiency disorders, either primary or acquired
Human immunodeficiency virus (HIV) infection
Human immunodeficiency virus (HIV) infection
History of human immunodeficiency virus (HIV) infection
DONOR: Human immunodeficiency virus (HIV) negative
Human immunodeficiency virus (HIV) infection
Anti-human immunodeficiency virus (HIV) 1 Antibody (alpha-HIV 1)
History of human immunodeficiency virus (HIV)
Donor human immunodeficiency virus (HIV) negative
Human immunodeficiency virus (HIV) antibody negative
Infection with human immunodeficiency virus (HIV)
Patients with human immunodeficiency virus (HIV)
History of human immunodeficiency virus (HIV) infection
Human immunodeficiency virus (HIV) = negative
Human immunodeficiency virus (HIV) infection
Negative human immunodeficiency virus (HIV) antibody
Human Immunodeficiency Virus (HIV) infection
Human immunodeficiency virus (HIV) associated lymphoma
Human immunodeficiency virus (HIV) negative (can be pending at this time)
Negative for human immunodeficiency virus (HIV)
Evidence of human immunodeficiency virus (HIV) infection
History of human immunodeficiency virus (HIV) infection.
History of human immunodeficiency virus (HIV)
DONOR: Human immunodeficiency virus (HIV) negative
Active cardiac disease and human immunodeficiency virus (HIV) infection
DONOR: Human immunodeficiency virus (HIV) negative
Human immunodeficiency virus (HIV) negative
History of liver disease or human immunodeficiency virus (HIV).
Human immunodeficiency virus (HIV) negative
DONOR: Human immunodeficiency virus (HIV) negative
Human Immunodeficiency Virus (HIV) infection.
Patients with human immunodeficiency virus (HIV)
Human immunodeficiency virus (HIV) infection
Patients must be human immunodeficiency virus (HIV) negative
Human immunodeficiency virus (HIV) negative
Human immunodeficiency virus (HIV) negative by standard blood testing
Human immunodeficiency virus (HIV) infection
Uncontrolled human immunodeficiency virus (HIV), CD4 count < 50
Patients with human immunodeficiency virus (HIV) are excluded
Presence of active infection including human immunodeficiency virus (HIV)
Human immunodeficiency virus (HIV) infection
History of human immunodeficiency virus (HIV)
Patients must be human immunodeficiency virus (HIV) non-reactive
History of human immunodeficiency virus (HIV) infection
Human immunodeficiency virus (HIV) infection
Human immunodeficiency virus (HIV) infection
History of human immunodeficiency virus (HIV) infection
Patients with human immunodeficiency virus (HIV) infection
Donor human immunodeficiency virus (HIV) negative (if autologous product – patient must be HIV negative)
Human immunodeficiency virus (HIV) infection by clinical history.
Diagnosis of immunodeficiency including history of human immunodeficiency virus (HIV)
No history of human immunodeficiency virus (HIV) or active infections
Human immunodeficiency virus (HIV) infection
Has a known history of Hepatitis B or known active Hepatitis C virus infection.
Current known active infection with HIV, hepatitis B virus, or hepatitis C virus
Has known active Hepatitis B or known active Hepatitis C virus infection.
Subjects with known active human immunodeficiency virus, hepatitis B virus, or hepatitis C virus infection
Current known active infection with HIV, hepatitis B virus, or hepatitis C virus.
Has a known history of hepatitis B or known active hepatitis C virus infection
Active hepatitis B and hepatitis C virus infection
Known active hepatitis A, B, or C virus infection
Known infection with human immunodeficiency virus or chronic infection with hepatitis B virus (hepatitis B surface antigen positive) or hepatitis C virus (anti hepatitis C virus positive)
Has a known history of Hepatitis B or known active Hepatitis C virus infection
Positive Hepatitis C virus antibody (HCVAb): hepatitis C virus RNA by PCR is necessary. Detectable hepatitis C virus RNA suggests chronic hepatitis C
Evidence of hepatitis B virus, hepatitis C virus or known HIV infection
Has known active hepatitis B or hepatitis C virus infection.
Evidence of hepatitis B virus, hepatitis C virus or known HIV infection
Active HIV, hepatitis C virus, or hepatitis B virus infection(s)
Known active hepatitis A, B or C virus infection
Clinically active infection with hepatitis B or hepatitis C virus
Has evidence of active hepatitis B virus or hepatitis C virus
Active infection with hepatitis B or hepatitis C virus
Known hepatitis B virus, hepatitis C virus or HIV infection
Has known active infection with hepatitis B virus or hepatitis C virus
Must not have evidence of previous or current infection with hepatitis B virus
Known active hepatitis B virus hepatitis, or known active hepatitis C virus
Known active hepatitis C virus, or known active hepatitis B virus
Known hepatitis B virus, hepatitis C virus or HIV infection
Known active infection with HIV, hepatitis B virus, or hepatitis C virus
Patients with positive hepatitis C virus
Known hepatitis B virus, hepatitis C virus or HIV infection
Known HIV infection or active Hepatitis B or Hepatitis C virus infection
Subjects who have an active hepatitis B virus or hepatitis C virus infection requiring treatment as defined in the protocol
Evidence of hepatitis B virus or hepatitis C virus infection or risk of reactivation.
Known history of Hepatitis B or known active Hepatitis C virus.
Ongoing or active systemic infection, known human immunodeficiency virus (HIV) positive, known active hepatitis B virus hepatitis, or known active hepatitis C virus hepatitis
Active infection with hepatitis A, B or C virus
Known active hepatitis C virus, or known active hepatitis B virus
Clinically active infection with hepatitis B or hepatitis C virus
Patients with active liver disease, for example, due to hepatitis B virus, hepatitis C virus, autoimmune hepatic disorder, or sclerosing cholangitis
Known active infection with HIV or Hepatitis B or C virus
Evidence of hepatitis B virus or hepatitis C virus infection or risk of reactivation.
Have active or uncontrolled clinically serious hepatitis B virus or hepatitis C virus infection.
Known infection with HIV or chronic infection with hepatitis B virus or hepatitis C virus
Evidence of hepatitis B virus, hepatitis C virus or known HIV infection
Known history of human immunodeficiency virus (HIV), active hepatitis C virus, active hepatitis B\r\nvirus infection, or any uncontrolled active systemic infection \r\n* Patients with inactive hepatitis B infection must adhere to hepatitis B reactivation prophylaxis unless contraindicated
Active or latent virus disease (HIV, hepatitis B and hepatitis C)
Known active hepatitis C virus, or known active hepatitis B virus
Known to be HIV positive, active hepatitis C virus, or active hepatitis B virus
Known clinically active infection with hepatitis B or hepatitis C virus
Patients with known active hepatitis B virus or hepatitis C virus acute or chronic infection
Ongoing or active systemic infection, known human immunodeficiency virus (HIV) positive, known active hepatitis B virus hepatitis, or known active hepatitis C virus hepatitis
Known history of human immunodeficiency virus (HIV) or active hepatitis C virus or active hepatitis B virus infection, or any uncontrolled active systemic infection \r\n* Patients with inactive hepatitis B infection must adhere to hepatitis B reactivation prophylaxis unless contraindicated
Evidence of hepatitis B virus, hepatitis C virus or known HIV infection
Known hepatitis B virus, hepatitis C virus or HIV infection
Patients with active liver disease, for example, due to hepatitis B virus, hepatitis C virus, autoimmune hepatic disorder, or sclerosing cholangitis
Documentation of hepatitis B virus and hepatitis C virus serology is required
Clinical evidence of active infection of any type, including hepatitis B or C virus
Known hepatitis B virus, hepatitis C virus or HIV infection;
Ongoing or active systemic infection, known human immunodeficiency virus (HIV) positive, known active hepatitis B virus hepatitis, or known active hepatitis C virus hepatitis
Known active Hepatitis B or Hepatitis C virus infection
Has a known history of Hepatitis B or known active Hepatitis C virus infection
Active infection with Hepatitis B virus or Hepatitis C virus
Detectable Hepatitis C virus (indicative of active Hepatitis C)
Active hepatitis B and C virus infection
Known active infection with hepatitis A, B or C virus
Hepatitis B Virus, or Hepatitis C Virus infection (subjects with laboratory evidence of Hepatitis B Virus clearance may be enrolled).
Known active infection with HIV, Hepatitis B or C virus
Known active hepatitis B virus infection
Evidence of hepatitis B virus or hepatitis C virus infection or risk of reactivation.
Currently known active infection with HIV, hepatitis B or C virus
Active hepatitis C virus
Active hepatitis B or C virus
Active infection with Hepatitis B virus or Hepatitis C virus
Has a known history of Hepatitis B or known active Hepatitis C virus infection.
Has acute or chronic active hepatitis B virus or hepatitis C virus infection or received treatment with nucleotide analogs such as those used in the treatment of hepatitis B virus (eg, lamivudine, adefovir, tenofovir, telbivudine, entecavir), ribavirin, or interferon alpha within 12 weeks of initiation of study treatment.
Has acute or chronic active hepatitis B virus or hepatitis C virus infection or received treatment with nucleotide analogs such as those used in the treatment of hepatitis B virus (eg, lamivudine, adefovir, tenofovir, telbivudine, and entecavir), ribavirin, or interferon alpha within 12 weeks of initiation of study treatment.
Patients must not have a known history of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C infection that is untreated and/or with a detectable viral load
Patients with known human immunodeficiency virus (HIV) infection, infectious hepatitis, type A, B or C, active hepatitis, or hepatic insufficiency
Previously known infection with human immunodeficiency virus (HIV); or hepatitis B or hepatitis C infection.
History of human immunodeficiency virus (HIV) infection or chronic hepatitis B or C
Known history of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C.
Known history of human immunodeficiency virus (HIV), or known active hepatitis A, B, or C infection (hepatitis B carriers with normal liver function tests [LFTs] and undetectable viral loads are allowed)
Have a symptomatic human immunodeficiency virus infection or symptomatic activated/reactivated hepatitis A, B, or C (screening is not required).
Active human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C infection.
Known chronic infection with human immunodeficiency virus (HIV) or viral hepatitis
Has known human immunodeficiency virus (HIV) and/or Hepatitis B or C infection(s).
Known active Hepatitis B (HepB), Hepatitis C (HepC) or human immunodeficiency virus (HIV) infection.
Known infection with Human Immunodeficiency Virus (HIV), and/or active infection with hepatitis B, or hepatitis C.
Known history of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C infection or known history of tuberculosis
Active human immunodeficiency virus (HIV) or hepatitis B or C infection
No active or chronic infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
No known active or chronic infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C; testing is not required unless clinically suspected
Known Human Immunodeficiency Virus (HIV) infection and/or active Hepatitis B or Hepatitis C infection
Known human immunodeficiency virus (HIV) infection or active hepatitis B (defined as hepatitis B surface antigen–positive) or C (defined as hepatitis C antibody–positive)
No human immunodeficiency virus (HIV) infection or active hepatitis B or C.
Patients must not have known human immunodeficiency virus (HIV) infection, active hepatitis B and/or hepatitis C.
Have a symptomatic human immunodeficiency virus infection or symptomatic activated/reactivated hepatitis B or C.
Subject has known human immunodeficiency virus (HIV), hepatitis B or hepatitis C infection or is known to be a carrier of hepatitis B or C.
Active infection requiring systemic therapy including tuberculosis, hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) is NOT permitted
Patients with conditions requiring immunosuppressive medications or chronic infections (including human immunodeficiency virus [HIV] infection, hepatitis B and C)
CRITERIA FOR SCREENING: Known active hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection
Patients with human immunodeficiency virus (HIV) or active hepatitis B or hepatitis C infection are ineligible
Patients with human immunodeficiency virus (HIV) or active hepatitis B or hepatitis C infection are ineligible
Known hepatitis B, hepatitis C or human immunodeficiency virus (HIV) infection.
Active human immunodeficiency virus (HIV), hepatitis B, or hepatitis C infection
Patients with known human immunodeficiency virus (HIV) infection or chronic or acute hepatitis B or C are not eligible; Note: Patients do not need to have HIV, hepatitis B, or hepatitis C testing at screening
Active hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection
History of human immunodeficiency virus (HIV) infection or active hepatitis B or C
Any history of human immunodeficiency virus (HIV) or hepatitis B infection
Patient has a known history of human immunodeficiency virus (HIV) infection or chronic, active hepatitis B (testing not mandatory)
Known human immunodeficiency virus (HIV), active hepatitis A, or hepatitis B or C infection
Infection with human immunodeficiency virus (HIV) or chronic infection with hepatitis B virus or hepatitis C virus.
Known human immunodeficiency virus (HIV) infection or chronic hepatitis B or C
No human immunodeficiency virus (HIV) infection or active hepatitis B or C
No known clinical finding or suspicion of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C
Active infection (eg, human immunodeficiency virus [HIV] or viral hepatitis)
Patients with known human immunodeficiency virus (HIV) infection or hepatitis
Active infection (eg, human immunodeficiency virus [HIV] or viral hepatitis)
Known positive test for human immunodeficiency virus infection (HIV), or active hepatitis B or hepatitis C infection.
Known active hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection
Known active infection with human immunodeficiency virus (HIV), hepatitis B, hepatitis C or cytomegalovirus (CMV)
Has a known history of human immunodeficiency virus (HIV) (HIV1/2 antibodies), hepatitis B, or hepatitis C infection
DONOR: Active human immunodeficiency virus (HIV) or hepatitis B or C infection
Subjects must not have active hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection
Known human immunodeficiency virus (HIV), hepatitis B, or hepatitis C infection; testing is not required as part of this study
Known immunosuppressive disease, autoimmune disease or human immunodeficiency virus infection, hepatitis B or hepatitis C
Active infection including tuberculosis, hepatitis B, hepatitis C, or human immunodeficiency virus (HIV).
Be on immunosuppressive therapy or have human immunodeficiency virus (HIV) infection or active hepatitis B or C
Patients with known hepatitis B or C or human immunodeficiency virus (HIV) infection
Known active hepatitis B infection, known history of hepatitis C or human immunodeficiency virus (HIV) infection
Subject has a known infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C
Have a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies), hepatitis B, or hepatitis C infection
Active hepatitis B or hepatitis C or known human immunodeficiency virus (HIV) infection
Patients with known human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C
Patient has known human immunodeficiency virus (HIV) or hepatitis C infection; baseline testing for HIV or hepatitis C is not required
Known history of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C; testing is not required in the absence of clinical findings or suspicion
Patients with known human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C
Known active human immunodeficiency virus (HIV), hepatitis B or C or infection; exception for patients with hepatitis B on antivirals and low viral load, to be determined at the discretion of the investigator
No active or chronic infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
Patients with a known history of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C infection
Positivity for human immunodeficiency virus (HIV)-1/HIV-2, Hepatitis B virus, and Hepatitis C virus active infection
History of chronic or recurrent infection including but not limited to human immunodeficiency virus (HIV), hepatitis B or hepatitis C
Positivity for human immunodeficiency virus (HIV)-1/HIV-2, hepatitis B virus, and hepatitis C virus active infection
In suspected patients no active or chronic infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
Patients with active human immunodeficiency virus (HIV), hepatitis B or hepatitis C infection
Patients with known active human immunodeficiency virus (HIV), hepatitis A, hepatitis B, or hepatitis C infection
Hepatitis C infection, chronic infection with hepatitis B, infection with human immunodeficiency virus (HIV), or evidence of hepatic insufficiency
Known infection with human immunodeficiency virus (HIV), hepatitis B or C
Patients with human immunodeficiency virus (HIV), hepatitis B or hepatitis C infection are ineligible
Known infection with human immunodeficiency virus (HIV), hepatitis B or C
Active infection including human immunodeficiency virus (HIV) and untreated hepatitis B, and hepatitis C. Screening for chronic conditions is not required.
Any evidence of active infection including active Hepatitis B, Hepatitis C or human immunodeficiency virus
No known active or chronic infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
ORAL CAVITY SQUAMOUS CELL CARCINOMA COHORT: Known infection with hepatitis B, hepatitis C, or human immunodeficiency virus (HIV)
Known active infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C.
Known history of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C.
Known hepatitis B, hepatitis C or human immunodeficiency virus (HIV) infection.
No infection with human immunodeficiency virus (HIV) and no known history of hepatitis B or hepatitis C virus indicating acute or chronic infection or active tuberculosis (TB)
Participants who have a known active infection requiring systemic therapy, including human immunodeficiency virus (HIV), hepatitis B, and hepatitis C
Uncontrolled infection with human immunodeficiency virus (HIV) or chronic hepatitis B or C.
Known active infection with human immunodeficiency virus, hepatitis B, or hepatitis C
Known chronic hepatitis B or C, or human immunodeficiency virus (HIV) infection
Known chronic infection with human immunodeficiency virus, hepatitis B, or hepatitis C.
Current infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C. Patients will have serologic testing performed during screening for HIV and hepatitis B and C. Any serologic results suggestive of an ongoing viral infection will be further investigated as necessary to clarify the patient’s status
Patients with a known history of human immunodeficiency virus (HIV) infection or active hepatitis B or hepatitis C
No active or chronic infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
Evidence of active hepatitis B (HepB), hepatitis C (HepC), or Human Immunodeficiency Virus (HIV) infection.
Known human immunodeficiency virus (HIV) or known active hepatitis B or hepatitis C infection for participants not receiving obinutuzumab pretreatment
Active or prior history of human immunodeficiency virus (HIV) infection, hepatitis B or C (screening for all three is mandatory prior to study)
Evidence for infection including wound infections, Human Immunodeficiency Virus (HIV) or any type of Hepatitis
Subject known to have acute or chronic active hepatitis B, hepatitis C, or human immunodeficiency virus infection will also be excluded.
History of human immunodeficiency virus (HIV) infection, active hepatitis B (chronic or acute), or hepatitis C infection
EXCLUSION FOR COLLECTION OF T CELLS/PBMCS: Patients with active human immunodeficiency virus (HIV), hepatitis B, or hepatitis C infection
Known human immunodeficiency virus (HIV) infection or chronic hepatitis B
Subject has a known history of infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
Known history of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C; testing is not required in the absence of clinical findings or suspicion; for guidance in defining active infection for hepatitis B, please refer to the World Health Organization (WHO) guidelines
Active infection with hepatitis B or C or human immunodeficiency virus (HIV)
Known human immunodeficiency virus (HIV), active hepatitis A, or hepatitis B or C infection
Confirmed diagnosis of human immunodeficiency virus (HIV) infection or active viral hepatitis
History of hepatitis B or C, human immunodeficiency virus (HIV), tuberculosis or a chronic infection of any type
Infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C virus
Known immunodeficiency or human immunodeficiency virus (HIV), hepatitis B, or hepatitis C infection; antibody to hepatitis B or C without evidence of active infection may be allowed
Known active human immunodeficiency virus (HIV), Hepatitis B or Hepatitis C infection on antiviral treatment
Active infection with hepatitis B or C or human immunodeficiency virus (HIV)
Known infection with human immunodeficiency virus (HIV), hepatitis B or C
Known hepatitis B or C virus, or human immunodeficiency virus (HIV) infection
History of human immunodeficiency virus (HIV), hepatitis B or hepatitis C infection.
Subjects with a known history of hepatitis B or C or human immunodeficiency (HIV) infection.
Active infection including hepatitis B, hepatitis C or human immunodeficiency virus (HIV);
Known hepatitis B, hepatitis C or human immunodeficiency virus (HIV) infection
Known history of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C; testing is not required in the absence of clinical findings or suspicion
Active infection including hepatitis B, hepatitis C or human immunodeficiency virus (HIV)
No active or chronic infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
Known human immunodeficiency virus (HIV) infection or chronic hepatitis B or C
Known human immunodeficiency virus (HIV), hepatitis B and hepatitis C infection
COHORT A: No active or chronic infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C (negative screening tests required)
Active hepatitis B, active hepatitis C, or any human immunodeficiency virus (HIV) infection
Patients with human immunodeficiency virus (HIV), active hepatitis B or hepatitis C infection
Known infection with human immunodeficiency virus, Hepatitis B, or Hepatitis C
Positive for hepatitis B, hepatitis C or human immunodeficiency virus (HIV) infection
Active human immunodeficiency virus (HIV), hepatitis A, B or C infection
Infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
No additional screening intended for human immunodeficiency virus (HIV) or hepatitis infection
Known chronic infection with human immunodeficiency virus (HIV) or viral hepatitis
Known history of human immunodeficiency virus or hepatitis C, or active infection with hepatitis B or C
No active or chronic infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
Known human immunodeficiency virus (HIV) infection, hepatitis B or Hepatitis C infection
Documented human immunodeficiency virus (HIV), active bacterial infections, active or chronic hepatitis B, or hepatitis C infection
Known positive test for human immunodeficiency virus (HIV), hepatitis C virus, or acute or chronic hepatitis B infection
No known active or chronic infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C; patients should be assessed for high risk behaviors that may result in these infections, such as intravenous drug use or multiple sexual partners; the assessment should be noted
No known active or chronic infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
Known history of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C; testing is not required in the absence of clinical findings or suspicion
No known active or chronic infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
Active hepatitis or human immunodeficiency virus (HIV) infection
Patients with human immunodeficiency virus (HIV) and active hepatitis B or hepatitis C infection are ineligible
Known Human Immunodeficiency Virus (HIV) infection, chronic hepatitis B or C (unless associated with hepatocellular cancer)
Human immunodeficiency virus (HIV), hepatitis B and/or hepatitis C infection
Patients with human immunodeficiency virus (HIV), hepatitis B or hepatitis C infection
No known human immunodeficiency virus (HIV) infection or chronic hepatitis B or hepatitis C infection
Known history of Human Immunodeficiency Virus (HIV) infection or chronic hepatitis B or C
Evidence of infection with human immunodeficiency virus (HIV) or viral hepatitis
Known history of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C.
Active hepatitis B, active hepatitis C, or any human immunodeficiency virus (HIV) infection at the time of screening
Uncontrolled human immunodeficiency virus (HIV), hepatitis B, or hepatitis C infection
Also, known human immunodeficiency virus (HIV) infection or chronic hepatitis B or C
Known diagnosis of human immunodeficiency virus (HIV) infection, hepatitis B or hepatitis C
Subject has known historical or active infection with HIV (human immunodeficiency virus), hepatitis B, or hepatitis C or subject receiving immunosuppressive or myelosuppressive medications that would, in the opinion of the Investigator, increase the risk of serious neutropenic complications.
No active or chronic infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
Patients with known human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C
Known confirmed diagnosis of human immunodeficiency virus (HIV) infection or active viral hepatitis (hepatitis B or hepatitis C)
Known human immunodeficiency virus (HIV) infection or chronic hepatitis B or C
Active infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C, or HIV-seropositive
Known human immunodeficiency virus (HIV) or hepatitis B or C infection
Patients with active hepatitis B or C infections or a history of human immunodeficiency virus (HIV) infection
Known human immunodeficiency virus (HIV) infection or chronic hepatitis B or C; must test during screening if history is not known
No active or chronic infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
Previously known infection with human immunodeficiency virus (HIV); or, hepatitis B or C requiring treatment;
Known and actively treated infection with human immunodeficiency virus (HIV), hepatitis B or C
Infection with hepatitis B or C, or history of human immunodeficiency virus (HIV) infection, or receiving immunosuppressive or myelosuppressive
Known human immunodeficiency virus (HIV) infection or active hepatitis B (defined as hepatitis B surface antigen–positive) or C (defined as hepatitis C antibody–positive)
Patient with known historical or active infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C
Human immunodeficiency virus (HIV) infection or chronic hepatitis B or C; negative screening tests for HIV, hepatitis B, and hepatitis C are required
History of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C infection
Known active hepatitis B, hepatitis C or Human Immunodeficiency Virus (HIV) infection.
Known history of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C. Testing is not required in the absence of clinical findings or suspicion.
Active Human Immunodeficiency Virus (HIV) or hepatitis B or C infection
Infection with human immunodeficiency virus, hepatitis B, or hepatitis C
Subjects may not have known human immunodeficiency virus (HIV), active hepatitis A, or hepatitis B or C infection
Known human immunodeficiency virus (HIV) infection or chronic hepatitis B or C
Hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection
Known or suspected human immunodeficiency virus (HIV) or hepatitis A(acute), B or C infection
No active or chronic infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
Known human immunodeficiency virus (HIV) infection or chronic hepatitis B or C
Known human immunodeficiency virus (HIV) infection or chronic hepatitis B or C
Known history of human immunodeficiency virus (HIV) infection or chronic hepatitis B or C; testing for these is not required at baseline
Known human immunodeficiency virus, Hepatitis B or Hepatitis C infection.
Patients with human immunodeficiency virus infection, hepatitis B, or hepatitis C due to confounding effects on immune system
Patients with human immunodeficiency virus infection, hepatitis B, or hepatitis C infection due to confounding effects on immune function
Patients with human immunodeficiency virus infection, hepatitis B, or hepatitis C infection
Known human immunodeficiency virus (HIV) infection or chronic hepatitis B or C
Patients with clinically significant infection, including known human immunodeficiency virus (HIV), human herpesvirus-8 (HHV-8), hepatitis C infection, or known hepatitis B surface antigen positivity are not eligible
Patients with active hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection
Patients with known human immunodeficiency virus (HIV) infection or viral hepatitis
Have a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies), hepatitis B, or hepatitis C infection
History of or current human immunodeficiency virus (HIV) or hepatitis C virus infection
History of known active infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C
History of known active infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
Known history of or known active infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C
Known history of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C
History of human immunodeficiency virus (HIV), hepatitis B, or active hepatitis C infection
Known immunosuppressive disease, autoimmune condition, and/or chronic viral infection (eg, human immunodeficiency virus [HIV], hepatitis)
History of or active hepatitis B or hepatitis C or human immunodeficiency virus (HIV) infection
Patient has a known history of human immunodeficiency virus (HIV) or active hepatitis B or active hepatitis C infection (testing not mandatory)
Known positive test for human immunodeficiency virus (HIV), hepatitis C virus, or acute or chronic hepatitis B infection
Active viral hepatitis or symptomatic human immunodeficiency virus (HIV) infection
Participants with known human immunodeficiency virus (HIV) infection, hepatitis B carrier state or with clinical evidence of hepatitis B
Known human immunodeficiency virus (HIV) seropositive or known hepatitis B or hepatitis C infection.
Is previously diagnosed human immunodeficiency virus (HIV) infection or active hepatitis B or C.
Human immunodeficiency virus (HIV), or active hepatitis B or C infection
